Document:

EX-10.15

 Exhibit 10.15 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

License and Collaboration Agreement 

Between 
 Visterra, Inc.

 and 
 Serum
Institute of India Ltd. 
 August 7, 2015 

 LICENSE AND COLLABORATION AGREEMENT

 This LICENSE AND COLLABORATION AGREEMENT (the
“Agreement”) is entered into on August 7, 2015 (the “Effective Date”) between VISTERRA, INC., a Delaware corporation with its principal place of business at One Kendall
Square, Suite B3301, Cambridge, MA 02139 (“Visterra”), and SERUM INSTITUTE OF INDIA LTD., a company incorporated under the Companies
Act, 1956, and having its Registered Office at 212/2, Off Soli Poonawalla Road, Hadaspar, Pune 411028, India (“SIIL”). Visterra and SIIL are sometimes referred to herein individually as a “Party” and collectively as
the “Parties.” 
 RECITALS 

WHEREAS, Visterra is developing its proprietary antibody VIS513 for the treatment of Dengue Fever
infections; 
 WHEREAS, SIIL has substantial expertise in the research, development, manufacture,
distribution, sales, marketing and distribution of pharmaceutical products in the Licensed Territory and the Option Territory (as defined below); and 

WHEREAS, Visterra desires to grant to SIIL, and SIIL desires to obtain, the right to develop, manufacture
and commercialize product(s) containing VIS513 for the treatment of Dengue Fever infections in the Licensed Territory all on the terms and conditions set forth herein; 

NOW THEREFORE, in consideration of the foregoing premises and the mutual promises,
covenants and conditions contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which is acknowledged by the Parties, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

 As used in this Agreement, the following initially capitalized terms, whether used in the singular or plural form, shall have the
meanings set forth in this Article 1. 
 1.1. “Adverse Event” means any side effect, injury, toxicity or sensitivity
reaction, or any unexpected incident, and the severity thereof, whether or not determined to be attributable to any Product, including, without limitation, a medical occurrence temporarily associated with the use of a medicinal product but not
necessarily causally related. 
 1.2. “Affiliate” means, with respect to a particular Party, a person,
corporation, partnership, or other entity that controls, is controlled by or is under common control with such 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 1

 
Party. For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”)
means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting
stock of such entity, or by contract or otherwise. 
 1.3. “Business Day” means a day other than (a) a Saturday
or a Sunday, (b) a bank or other public holiday in Boston, MA, USA, (c) a bank or other public holiday in Pune, India, or (d) with respect to administrative matters, but not the calculation and payment of amounts to be paid in
connection with this Agreement, the nine (9) consecutive days beginning on December 24th and continuing through January 1st and
the five (5) consecutive days of Diwali (as celebrated in Pune, India) to the extent not already covered in (a), (b) or (c). 

1.4. “Calendar Quarter” means each of the three (3)-month periods ending on
March 31, June 30, September 30, and December 31 of any Calendar Year, or the applicable portion of such period. 

1.5. “Calendar Year” means each twelve (12)-month period commencing on January 1, and ending on December 31,
or the applicable portion of such period; provided, that the first Calendar Year commences on the Effective Date and ends on December 31, 2015. 

1.6. “Caribbean” means Antigua and Barbuda, Aruba, the Bahamas, Barbados, Cuba, Curacao, Dominica, Dominican Republic,
Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines and Trinidad and Tobago. 
 1.7.
“Central America” means Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Panama. 
 1.8.
“Commercialization” means all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison activities,
Manufacturing for commercial purposes, marketing, pricing, reimbursement, sale, and distribution of the Product, including: (a) strategic marketing, sales force detailing, advertising, medical education and liaison, and market and Product
support; (b) any post-marketing clinical studies for use in generating data to be submitted to Regulatory Authorities (and all associated reporting requirements); and (c) all customer support, Product distribution, invoicing and sales
activities. “Commercialize” and “Commercializing” shall have correlative meanings. 
 1.9.
“Commercially Reasonable Efforts” means: (a) where applied to carrying out specific tasks and obligations of a Party under this Agreement, expending reasonable, diligent, good faith efforts and resources to accomplish such
task or obligation as such Party (on its own or acting through any of its Affiliates, sublicensees or subcontractors) would normally use to accomplish a similar task or obligation under similar circumstances; and (b) where applied to
Development, Manufacture or Commercialization of a Product, the use of reasonable, diligent, good faith efforts and resources, in an active and ongoing program, as normally used by similarly-situated companies with respect to a company product
having comparable commercial potential, stage of development, medical/scientific, technical and regulatory profile, and 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 2

 
intellectual property protection, taking into account all Commercially Relevant Factors at the time such efforts are to be expended. 

1.10. “Commercially Relevant Factors” means, with respect to a Product, including as applicable to such Product, all
relevant factors that may affect the Development, Regulatory Approval or Commercialization of such Product, including (as applicable): safety, efficacy, quality or stability; product profile (including product modality, category and mechanism of
action); stage of Development or life cycle status; Development, Regulatory Approval, manufacturing, and Commercialization costs and risk; feasibility of manufacture; the likelihood of obtaining Regulatory Approvals (including satisfactory price
approvals) and the timing of such approvals; the current guidance and requirements for Regulatory Approval and the current and projected regulatory status; labeling or anticipated labeling; the then-current competitive environment external to the
Parties and the likely competitive environment external to the Parties at the time of projected entry into the market (i.e., not taking into consideration any other Products or other products of the Parties); past performance;
present and future market potential; existing or projected pricing, sales, reimbursement and profitability; pricing or reimbursement changes in relevant countries; proprietary position, strength and duration of patent protection and anticipated
exclusivity; and other scientific, technical, regulatory, and commercial factors that the decision-making Party reasonably believes to be relevant to such Product. 

1.11. “Confidential Information” means, with respect to a Party, all non-public, confidential or proprietary
Information of such Party that is disclosed to the other Party (or its employees, consultants, Affiliates, officers, directors, attorneys, accountants, advisors or agents) on or after the Effective Date, whether in oral, written, graphic, or
electronic form, together with other Information which a reasonable person would conclude is intended to remain confidential due to its nature or the circumstances under which it is disclosed. All Information disclosed by either Party pursuant to
the Confidential Disclosure Agreement between the Parties dated June 10, 2013, as amended as of June 10, 2014, shall be deemed to be such Party’s Confidential Information disclosed hereunder. 

1.12. “Control” means, with respect to any material, Information, or intellectual property right, that a Party or its
Affiliates owns or has a license or right to such material, Information, or intellectual property right and, in each case, has the ability to grant to the other Party access, a license, or a sublicense (as applicable) to the foregoing on the terms
and conditions set forth in this Agreement without violating the terms of any then-existing agreement or other arrangement with, or obtaining the consent of, any Third Party. Notwithstanding the foregoing, material, Information or intellectual
property rights subject to a Third Party payment obligation (other than payment obligations arising under the MIT Agreement) as a result of the grant of a license to the other Party or arising out of the practice or use of such material, Information
or intellectual property right by the other Party shall only be deemed to be “Controlled” by a Party if the other Party agrees in writing to reimburse the granting Party for all such payments to the relevant Third Party. 

1.13. “Develop” or “Development” means all activities relating to preparing and conducting
preclinical testing, toxicology testing, human clinical studies, and regulatory activities (e.g., Regulatory Approval Applications) with respect to the Product and post-Regulatory Approval regulatory activities in connection with a Product, together
with the 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 3

 
Manufacturing of the Product for the purpose of conducting the foregoing activities. 

1.14. “Dollar” means a U.S. dollar, and “$” shall be interpreted accordingly. 

1.15. “European Union” or “EU” means the countries of the European Union as constituted on the
Effective Date and as it may be expanded or contracted from time to time after the Effective Date and their respective territories and possessions. 

1.16. “Field” means the treatment and prevention of Dengue Fever infections in humans. 

1.17. “First Commercial Sale” means the first sale to a Third Party of a Product in a given regulatory jurisdiction
after Regulatory Approval has been obtained in such jurisdiction. 
 1.18. “GAVI Alliance” means the Global
Alliance for Vaccines and Immunization (GAVI), an independent non-profit organization established under the laws of Switzerland, with the purpose of providing support for improvements of vaccinations and immunization in the poorest countries of the
world. 
 1.19. “GAVI-Eligible Countries” means all countries in the Licensed Territory which are deemed
GAVI-eligible countries by the GAVI Alliance, as such GAVI-eligible countries may be added or deleted by the GAVI Alliance from time to time, and any other country that may be added as a “Developing Country” under the MIT Agreement. As of
the Effective Date, India and Sri Lanka are the only GAVI-Eligible Countries in the Licensed Territory. 
 1.20. Generic
Product” means, with respect to a Product in the Field in a particular country in the Licensed Territory, another pharmaceutical product that is: (a) a Product; (b) approved for use in such country by the relevant Regulatory
Authority; and (c) commercialized by a Third Party who has not obtained the right or access to such product (through sublicense, subcontract or chain of distribution) from SIIL or its Affiliates or sublicensees. 

1.21. “Good Manufacturing Practice” means all applicable then-current standards for Manufacturing, including, as
applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Sections 210, 211, 601, 610 and 820, (b) European Directive 2003/94/EC and Eudralex 4, (c) the principles detailed in the ICH Q7
guidelines, and (d) the equivalent applicable Laws in any relevant country, each as may be amended and applicable from time to time. 

1.22. “Information” means any data, results, technology, business information and information of any type whatsoever,
in any tangible or intangible form, including know-how, trade secrets, practices, techniques, tools, methods, methodologies, designs, prototypes, processes, drawings, inventions, developments, specifications, formulations, formulae, materials or
compositions of matter of any type or kind (patentable or otherwise), software, algorithms, source code, personnel information, marketing reports, customer lists, pricing information, financial information, marketing plans, development plans,
expertise, technology, models, clinical trial designs, test data (including pharmacological, biological, chemical, biochemical, 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 4

 
toxicological, preclinical and clinical test data), analytical and quality control data, stability data, other study data, databases and procedures. 

1.23. “Initiation” means, with respect to a clinical study of a Product, the first dosing of the first human subject
for such clinical study with the Product. 
 1.24. “Laws” means all laws, statutes, rules, regulations,
ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 

1.25. “Licensed Antibody” means Visterra’s proprietary engineered monoclonal antibody known as VIS513 having the
amino acid sequence set forth on Exhibit A attached hereto. 
 1.26. “Licensed Territory” means India,
Pakistan, Bangladesh, Nepal, Bhutan, Maldives and Sri Lanka. 
 1.27. “Manufacture” or
“Manufacturing” means any and all activities directed to producing, manufacturing, scaling-up, processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping and storage of a pharmaceutical
product or any component or form thereof (including production of drug substance and drug product, in bulk form, for preclinical and clinical studies and for Commercialization). 

1.28. “MIT Agreement” means that certain Exclusive Patent License Agreement between the Massachusetts Institute of
Technology (“MIT”) and Visterra dated November 15, 2013, as amended from time to time. 
 1.29.
“MIT Patents” means the Patents licensed to Visterra pursuant to the MIT Agreement. 
 1.30. “Net
Sales” means the gross amount billed by SIIL and its Affiliates, excluding distributors and wholesalers, for any Product sold to Third Parties other than sublicensees as determined in accordance with SIIL’s accounting standards as
consistently applied, less a deduction of the following, in each case, to the extent actually accrued, discounted or credited, as applicable, and without duplication: 

(a) customary trade, quantity, or cash discounts to the extent actually allowed and taken; 

(b) amounts repaid or credited by reason of defects, rejections, recalls or returns; 

(c) to the extent separately stated on purchase orders, invoices, or other documents of sale, any taxes or other governmental charges
levied on the production, sale, transportation, delivery, or use of a Product which is paid by or on behalf of SIIL; 
 (d) outbound
transportation costs prepaid or allowed and costs of insurance in transit; 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 5

 (e) rebates and chargebacks to customers and third parties; 

(f) sales, transfers or other dispositions of Product for test marketing, sampling, promotional, charitable, compassionate use (or
similar programs), donations (for example, to non-profit institutions or government agencies), pre-clinical, clinical or regulatory purposes; and 

(g) amounts provided or credited to customers through coupons and other discount programs. 

Net Sales shall occur on the earlier of the receipt of payment or ninety (90) days after the date of billing for a Product. If a Product
is distributed at a discounted price that is substantially lower than the customary price charged by SIIL (taking into account customary pricing for a governmental entity), or distributed for non-cash consideration (whether or not at a discount),
Net Sales shall be calculated based on the non-discounted amount of the Product charged to an independent Third Party during the same Calendar Quarter or, in the absence of such sales, on the fair market value of the Product. 

Non-monetary consideration shall be valued based on the fair market value of such non-monetary consideration, including all relevant and
material elements of such consideration, as agreed by the Parties in good faith. 
 Net Sales shall be calculated only once with respect to
each Product sold by SIIL or its Affiliates, even if such Product is sold more than once in the course of its transfer to the ultimate end-user. The foregoing notwithstanding, Net Sales shall not include transfers among SIIL and any Affiliate unless
the recipient does not intend to further sell or transfer the Product and is the end user thereof. 
 1.31. “North
America” means Canada, the United States and Mexico and their respective territories and possessions. 
 1.32.
“Option Period” means the period beginning on the Effective Date and ending on the date that is [**] days following SIIL’s generation of top line clinical data from the first Phase 2 Clinical Study of the Product in
lab-confirmed Dengue Fever patients; provided, that the Option Period may be earlier terminated as set forth in Section 2.9(c). 

1.33. “Option Territory” means all countries and territories in the world excluding the Licensed Territory and the
Retained Territory. 
 1.34. “Patents” means (a) pending patent applications, issued patents, utility
models and designs, (b) provisionals, nonprovisionals, reissues, substitutions, confirmations, registrations, validations, re-examinations, revalidations, extensions, additions, continuations, continued prosecution applications, supplementary
protection certificates, PCTs, continuations-in-part, or divisions of or to any patents, patent applications, utility models or designs, and all patents issued on any of the foregoing and (c) any foreign equivalent or counterpart of the
foregoing. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 6

 1.35. “Phase 1 Clinical Study” means a clinical study in humans which
provides for the first introduction into humans of a pharmaceutical product, conducted in normal subjects or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, as further defined by Indian
Regulatory Authorities. 
 1.36. “Phase 2 Clinical Study” means a clinical study in humans of the safety,
dose ranging and efficacy of a pharmaceutical product, as further defined by Indian Regulatory Authorities, Federal Regulation 21 C.F.R. § 312.21(b) or its foreign equivalents. 

1.37. “Phase 3 Clinical Study” means a controlled clinical study, or a portion of a controlled study, in humans of the
efficacy and safety of a pharmaceutical product, which study (in its entirety or portion, as applicable), is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular indication in a
manner sufficient to file an application to obtain Regulatory Approval, as further defined by Indian Regulatory Authorities. 

1.38. “Product” means any product for the Field comprising or containing the Licensed Antibody, alone or in
combination with other active pharmaceutical ingredients or agents, in any and all forms, in current and future formulations, dosage forms and strengths, and delivery modes; provided, however, that Product shall not include another
therapeutically-active compound or antibody (other than a Licensed Antibody) that is Covered by or embodies any Patents or Information and that are, in either case, Controlled by Visterra or any of its Affiliates, without Visterra’s prior
written consent. 
 1.39. “Regulatory Approval” means, with respect to a Product in any country or jurisdiction, all
approvals, registrations, licenses or authorizations from the relevant Regulatory Authority in a country or jurisdiction that is specific to Product and necessary to market and sell such Product in such country or jurisdiction and related pricing
and reimbursement approvals, to the extent such approvals would be obtained in the ordinary course. 
 1.40.
“Regulatory Approval Application” means an application to the appropriate Regulatory Authority for Regulatory Approval in any particular country or jurisdiction (e.g., an NDA or BLA). 

1.41. “Regulatory Authority” means, in a particular country or regulatory jurisdiction, any applicable multinational,
federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity involved in granting Regulatory Approval or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement
approval of a Product in such country or regulatory jurisdiction. 
 1.42. “Regulatory Exclusivity” means
market or data exclusivity granted by a governmental authority to prevent the entry of Generic Products onto the market, including new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug
exclusivity, pediatric exclusivity and 180-day generic product exclusivity, or any equivalent of the foregoing in the Licensed Territory. 

1.43. “Regulatory Filings” means, with respect to the Product, any submission to a Regulatory Authority of any
appropriate regulatory application specific to the Product, and shall 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 7

 
include any submission to a regulatory advisory board and any supplement or amendment thereto. 

1.44. “Retained Territory” means all countries and territories in North America, Central America, the Caribbean, South
America and the EU and Australia, Japan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam. 

1.45. “Serious Adverse Events” means an Adverse Event which results in death or is immediately life-threatening or
results in persistent and significant disability/incapacity or results in congenital abnormally and medically important event or requires in-patient hospitalization or prolongation of existing hospitalization. 

1.46. “SIIL Know-How” means all Information Controlled by SIIL and used by or on behalf of SIIL to make, use and sell
Product. For clarity, SIIL Know-How excludes rights granted under the SIIL Patents. 
 1.47. “SIIL Manufacturing
Technology” means SIIL Know How and those SIIL Patents utilized by SIIL in the manufacture of a product containing the Licensed Antibody Products. 

1.48. “SIIL Patent” means all Patents that (a) are Controlled by SIIL or its Affiliates as of the Effective Date
or at any time during the Term (excluding SIIL’s interest in any Joint Patents), and (b) but for the licenses granted herein and assuming the issuance of the claims in any unissued claims part of a Valid Claim of any such Patent, would be
infringed by the developing, making, using, offering for sale, selling or importing of the Product in the territory contemplated by any relevant license herein. 

1.49. “SIIL Technology” means the SIIL Patents and SIIL Know-How. 

1.50. “South America” means Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname,
Uruguay and Venezuela. 
 1.51. “Taxes” means taxes (other than income taxes), duties, tariffs or other
governmental charges levied on the sale of Products, including consumption taxes. 
 1.52. “Third Party”
means any person or entity other than Visterra or SIIL or their respective Affiliates. 
 1.53. “Valid Claim”
means, with respect to any country: (a) a claim of an issued and unexpired patent (as may be extended through supplementary protection certificate or patent term extension or the like) to the extent such claim has not been revoked, held invalid
or unenforceable by a patent office, tribunal, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not
been disclaimed, denied or admitted to be invalid or unenforceable through reissue, post grant opposition, revocation, re-examination or disclaimer or otherwise; and (b) a claim of a pending patent application in such country covering the
applicable product, in each case that has been pending less than [**] years from the earliest date on which such patent application claims priority and which claim 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 8

 
was filed and is being prosecuted in good faith and has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. 

1.54. “Visterra Know-How” means all Information that is Controlled by Visterra or its Affiliates as of the Effective
Date or during the Term and is necessary or reasonably useful for the Development, Manufacture or Commercialization of the Licensed Antibody or Product in the Field. Without limiting the foregoing, except as set forth below, Visterra Know-How
includes all data, results and other Information generated from or obtained by clinical studies and other tests Controlled by Visterra or its Affiliates and any Information described in Regulatory Filings filed with any Regulatory Authority in the
Visterra Territory with respect to the Product to the extent Controlled by Visterra or its Affiliates. Notwithstanding the foregoing, Visterra Know-How shall not include Information controlled by a Third Party that acquires Visterra pursuant to an
Acquisition and such Information (a) existed as of the date of closing of such acquisition or merger or (b) was developed after the date of closing of such acquisition or merger without using Visterra Know-How or inventions claimed in
Visterra Patents. For clarity, Visterra Know-How excludes rights granted under the Visterra Patents and SIIL Technology. 
 1.55.
“Visterra Patents” means all Patents in the Licensed Territory that (a) are Controlled by Visterra or its Affiliates as of the Effective Date or at any time during the Term (excluding Visterra’s interest in any Joint
Patents), and (b) but for the licenses granted herein, would be infringed by the developing, making, using, offering for sale, selling or importing of the Licensed Antibody or Product by SIIL or its Affiliates in the Field in the Licensed
Territory. Notwithstanding the foregoing, Visterra Patents shall not include Patents controlled by a Third Party that acquires Visterra pursuant to an Acquisition if such Patents (a) existed as of the date of closing of such acquisition or
merger or (b) was developed after the date of closing of such acquisition or merger without using Visterra Know-How or inventions claimed in Visterra Patents. The Visterra Patents existing as of the Effective Date in the Licensed Territory are
set forth on Exhibit B attached hereto. For clarity, Visterra Patents exclude rights granted under the Visterra Know-How and SIIL Technology. 

1.56. “Visterra Technology” means the Visterra Patents and Visterra Know-How. 

1.57. “Visterra Territory” means (a) prior to the execution of an Option Amendment, the Retained Territory and
the Option Territory and (b) after the execution of an Option Amendment, the Retained Territory. 
 ARTICLE 2 

LICENSES AND TERRITORY OPTION 

2.1. License to SIIL under Visterra Technology. 

(a) License. Subject to the terms of this Agreement, Visterra hereby grants SIIL and its Affiliates during the Term (i) an
exclusive (even as to Visterra), non-sublicensable, royalty-bearing license and, as the case may be, sublicense subject to Section 2.1(b), under the Visterra Technology and Visterra’s interest in the Joint Patents, to research, Develop, have

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 9

 
Developed, make, have made, use, sell, offer for sale, have sold, import, export and otherwise Commercialize and exploit the Product in the Field in the Licensed Territory and (ii) a
non-exclusive, non-sublicensable, royalty-bearing license under the Visterra Technology to make and have made the Licensed Antibody and Product in the Netherlands, solely for export to, use or sale of the Product in the Licensed Territory. 

(b) Visterra Retained Rights. Visterra and its Affiliates hereby retain the exclusive right under the Visterra Technology to:
(i) practice Visterra Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more licensees; and (ii) practice and license Visterra Technology outside the scope of the
licenses granted to SIIL under Section 2.1(a), including to Develop Products for the purpose of obtaining Regulatory Approval outside the Licensed Territory, to make and have made Products for use outside the Licensed Territory, and to use, import,
offer for sale, sell and otherwise Commercialize Products but solely for end use outside of the Licensed Territory. 
 (c) MIT
Retained Rights. SIIL acknowledges that MIT retains the right on behalf of itself and all other non-profit research institutions to practice under the MIT Patents for research, teaching, and educational purposes to the extent specifically set
forth in the MIT Agreement. 
 2.2. License to Visterra. SIIL hereby grants Visterra: 

(a) during the Term, a non-exclusive, fully-paid, royalty free license, with the right to grant sublicenses to Third Party service
providers acting on Visterra’s behalf (subject to the restrictions set forth below), under the SIIL Technology solely to perform Visterra’s obligations under this Agreement; 

(b) a perpetual, royalty-free, fully-paid, non-exclusive license, with the right to grant sublicenses, under SIIL’s interest in
the Joint Patents to research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Products in the Visterra Territory; 

(c) a perpetual, non-exclusive or exclusive (to be mutually agreed by the Parties in good faith) license, with the right to grant
sublicenses (through multiple tiers), under the SIIL Manufacturing Technology to research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize products containing the Licensed Antibody for the Field in the
Visterra Territory, such license under this subsection (c) shall bear commercially reasonable consideration to be negotiated in good faith by the Parties, taking into account the commercial value of such SIIL Manufacturing Technology and scope
of license granted to Visterra; and 
 (d) a perpetual, non-exclusive license, with the right to grant sublicenses (through
multiple tiers), under the SIIL Technology (other than SIIL Manufacturing Technology) to research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize products containing the Licensed Antibody in the Field in the
Visterra Territory, which license shall (i) with respect to SIIL Technology that (A) covers or claims the composition, manufacture, use or sale of the Licensed Antibody or (B) was generated by or on

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 10

 
behalf of SIIL under this Agreement with respect to the Licensed Antibody, be royalty-free and fully-paid, and (ii) with respect to SIIL Technology that is not covered by subsection (d)(i)
above, bear commercially reasonable consideration to be negotiated in good faith by the Parties, which consideration shall be determined by the Parties taking into account the commercial value of such SIIL Technology and scope of license granted to
Visterra. 
 2.3. Rights of Reference. 

(a) Visterra hereby grants to SIIL and its Affiliates a “Right of Reference,” as that term is defined in 21 C.F.R. §
314.3(b) and any foreign counterpart to such regulation, to any Regulatory Filings Controlled by Visterra or any of its Affiliates on the Effective Date and during the Term and all data contained therein, in each case, that are necessary or useful
to Develop, Manufacture or Commercialize the Licensed Antibody or Product in the Field in the Licensed Territory in accordance with this Agreement. 

(b) SIIL hereby grants to Visterra a freely-sublicensable “Right of Reference,” as that term is defined in 21 C.F.R. §
314.3(b) and any foreign counterpart to such regulation, to any Regulatory Filings Controlled by SIIL or any of its Affiliates on the Effective Date and during the Term and all data contained therein, in each case, that are necessary or useful to
Develop, Manufacture or Commercialize the Licensed Antibody or Product in the Visterra Territory. 
 2.4. Negative Covenant; No
Implied License. SIIL covenants that it shall not, and it shall not permit any of its Affiliates to, use or practice any Visterra Technology outside the scope of the license granted to it under Section 2.1 above. Visterra covenants that it shall
not, and it shall not permit any of its Affiliates to, use or practice any SIIL Technology outside the scope of the license granted to it under Section 2.2. Except as set forth herein, neither Party shall acquire any license or other intellectual
property interest, by implication or otherwise, under any trademarks or Patents owned or Controlled by the other Party. 
 2.5.
Diversion. Each Party shall use Commercial Reasonable Efforts to ensure Products sold by, or with the permission of, such Party or its Affiliates or licensees is for end use in its respective territory. If a Party becomes aware that a product is
being diverted to another territory, then it shall promptly notify the other Party of the same with the full details available to it, and the Parties shall promptly investigate the matter and discuss and agree upon a commercially reasonable
remediation plan within sixty (60) days thereafter. Such plan shall be implemented within thirty (30) days thereafter. 

2.6. Other Products. During the Term, except pursuant to and in accordance with the terms of this Agreement, neither SIIL nor any of
its Affiliates shall directly or indirectly develop, manufacture or commercialize any therapeutic product containing an antibody as an active ingredient in the Licensed Territory that is indicated for the treatment of Dengue Fever infections in
humans. Visterra acknowledges that SIIL, as of the Effective Date, has existing development programs and activities with respect to treatments of Dengue Fever, and, notwithstanding anything to the contrary herein, except as set forth above in this
Section 2.6, this Agreement shall not in any way restrict SIIL’s freedom to exploit any product opportunities or to conduct development or commercialization activities, now and in future, against Dengue Fever either by

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 11

 
way of preventive products, curative products or therapeutic treatments. 
 2.7.
MIT Rights in India & Sri Lanka. The following applies to the extent specifically required by the MIT Agreement for Visterra’s compliance therewith. For clarity, SIIL is not a party to the MIT Agreement and has no direct
obligations to MIT pursuant to this Agreement. 
 (a) If Visterra or any of its Affiliates receives, or if MIT notifies
Visterra that it has received, a bona fide request from a capable Third Party for a license under the MIT Patents to Develop and Commercialize a Product at affordable prices in India or Sri Lanka and the Product is not being sold (including without
limitation sufficient supply to meet market demand at reasonable costs) or diligently developed for sale by SIIL or an Affiliate for end use in India or Sri Lanka, as applicable, then Visterra shall promptly notify SIIL of such inquiry (an
“Inquiry Notice”). So long as SIIL is not in material breach of its relevant obligations hereunder, Visterra shall use its best efforts to respond to MIT in connection with the Inquiry Notice in a manner agreed upon by the Parties,
provided that any response shall, to the extent consistent with Visterra’s reasonable good faith belief, include confirmation of SIIL’s compliance with its obligations hereunder and Visterra’s belief that exclusivity should be
maintained with respect to the license grants under Section 2.1 of the MIT Agreement. 
 (b) Within [**] months of such
Inquiry Notice, Visterra may enter into a non-exclusive sublicense agreement containing commercially reasonable terms and conditions with such Third Party for the requested Product in India or Sri Lanka, as applicable. SIIL acknowledges that if
Visterra does not grant a sublicense under the MIT Patents to the Third Party within [**] months of such Inquiry Notice, and MIT, at its sole discretion, determines that a sublicense to the Third Party is reasonable under the totality of the
circumstances (taking into account development efforts of SIIL and its Affiliates) to make Products available in India or Sri Lanka, as applicable, then MIT shall have the right to grant a non-exclusive license under the MIT Patents to such Third
Party in such territory. For clarity, the foregoing non-exclusive licenses contemplated under this Section 2.7(b) shall not apply to any Visterra Patents (other than the MIT Patents) licensed to SIIL hereunder. 

2.8. Disclosure of Know-How. Visterra shall, as soon as practicable after the Effective Date but in no event later than [**] months
after the Effective Date, and from time to time during the Term thereafter on the reasonable request of SIIL, disclose to SIIL in writing Visterra Know-How that is necessary for the Development, Manufacture or Commercialization of the Product.
Without limiting the foregoing, Visterra shall transfer the Visterra Know-How identified on Schedule 2.8 to SIIL in accordance with the timelines specified on Schedule 2.8. SIIL shall disclose to Visterra in writing the SIIL Know-How that is
licensed to Visterra as contemplated by this Agreement, (i) as soon as practicable after the Effective Date but in no event later than [**] months after the Effective Date, and from time to time during the Term thereafter on the reasonable
request of Visterra, with respect to SIIL Know-How under Section 2.2(a), and (ii) from time to time during the Term on the reasonable request of Visterra, with respect to SIIL Know-How under Section 2.2(d). 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 12

 2.9. Option Territory. 

(a) Grant of Option. During the Term and subject to the other terms and conditions of this Agreement, Visterra hereby grants SIIL an
exclusive option during the Option Period, exercisable in accordance with Section 2.9(b), for SIIL to obtain a non-exclusive, royalty-bearing license, under the Visterra Technology, to research, Develop, make, have made, use, sell, offer for sale,
have sold, import, export and otherwise Commercialize and exploit the Product in the Field in the Option Territory (the “Option”). 

(b) Exercise of Option.  

(i) Subject to Section 2.9(c), SIIL may exercise the Option at any time during the Option Period upon delivery of written notice to
Visterra (the “Option Exercise Notice”). If SIIL does not exercise the Option by the end of the Option Period, or if SIIL provides Visterra with written notification at any time prior to the end of the Option Period that it will not
exercise the Option, then the Option shall expire without being exercised, and Visterra shall have the right to, either by itself or with a Third Party, research, Develop, Manufacture and Commercialize the Product in the Option Territory without
further obligation to SIIL. 
 (ii) If SIIL exercises its Option within the Option Period then, promptly after
Visterra’s receipt of the Option Exercise Notice, the Parties shall negotiate in good faith, for a period of [**] days after Visterra’s receipt of such Option Exercise Notice (the “Negotiation Period”), an amendment to
this Agreement pursuant to which the Licensed Territory would be expanded to include the Option Territory on a non-exclusive basis and SIIL would agree to meet certain agreed upon Development and Commercialization diligence milestones within an
agreed upon time period (the “Option Amendment”). Within [**] days after the execution of the Option Amendment by both Parties, SIIL shall pay to Visterra a one-time, non-refundable and non-creditable upfront fee of [**] Dollars
($[**]). The Option Amendment shall only be effective upon Visterra’s receipt of such payment. If the Parties, despite good faith negotiations, are unable to enter into such Option Amendment within the Negotiation Period, then Visterra shall
have the right to, either by itself or with a Third Party, research, Develop, Manufacture and Commercialize the Product in the Option Territory without further obligation to SIIL 

(c) Option Acceleration.  

(i) If, any time during the Option Period, Visterra receives a bona fide request from a Third Party to discuss or negotiate an
agreement pursuant to which such Third Party would Develop and Commercialize the Product in the Option Territory (or one or more countries therein), Visterra shall so notify SIIL. SIIL shall have [**] days after its receipt of such notice to
exercise the Option as provided in Section 2.9(b). If SIIL does not exercise the Option by the end of such [**] day period, or if SIIL provides Visterra with written notification at any time prior to the end of such [**] day period that it does not
wish to exercise the Option, then the Option Period shall terminate, the Option shall expire without being exercised, and Visterra shall have the right to, either by itself or with a Third Party, research, Develop, Manufacture and Commercialize the
Product in the Option Territory without further obligation to SIIL. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 13

 (ii) If, at any time during the Option Period, SIIL elects to make reference in any
Regulatory Filing to any top-line clinical data from a Phase 2 Clinical Study of the Product in lab-confirmed Dengue Fever patients that was conducted by Visterra or a Third Party licensee, collaborator or contractor of Visterra, SIIL shall promptly
notify Visterra of such election. SIIL shall have [**] days after delivery of such notice to exercise the Option as provided in Section 2.9(b). If SIIL does not exercise the Option by the end of such [**] day period, or if SIIL provides Visterra
with written notification at any time prior to the end of such [**] day period that it does not wish to exercise the Option, then the Option Period shall terminate, the Option shall expire without being exercised, and Visterra shall have the right
to, either by itself or with a Third Party, research, Develop, Manufacture and Commercialize the Product in the Option Territory without further obligation to SIIL. 

ARTICLE 3 
 MANAGEMENT
AND GOVERNANCE 
 3.1. Joint Steering Committee. 

(a) Formation and Authority. Within thirty (30) days after the Effective Date, the Parties shall establish a joint steering
committee (the “Joint Steering Committee” or “JSC”) to provide input and exchange information concerning the Development, Manufacture, and Regulatory Approval process and Commercialization activities being conducted
by SIIL or its Affiliates hereunder with respect to the Product. Neither the JSC nor any subcommittee or alliance manager shall have any power to amend, modify, or waive compliance with this Agreement or increase the obligations of either Party. In
conducting themselves on the JSC and the subcommittees, and as alliance managers, and in exercising their rights under this Section 3.1, all representatives of either Party shall consider diligently, reasonably and in good faith all input received
from the other Party, and shall use reasonable efforts to reach unanimity, where required, on any decision or advice the JSC offers to either or both Parties. 

(b) Members. Within thirty (30) days following the Effective Date, each Party shall initially appoint two (2) representatives
to the JSC, each of whom shall have sufficient experience in the subject matter of this Agreement, and shall inform the other Party about the appointments. The JSC may change its size from time to time by mutual written consent of the Parties;
provided that the JSC shall at all times consist of an equal number of representatives of each Party. Each Party may replace its JSC representatives at any time upon at least ten (10) days prior notification, in writing or
electronically, to the other Party. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Upon prior notification, in writing or electronically, to the JSC, each Party may invite no more than two
(2) non-members to participate in the discussions and meetings of the JSC. Such participation shall be subject to the consent of both Parties, such consent not to be unreasonably withheld, conditioned or delayed. The JSC shall have a
chairperson, who shall serve for a term of one year, and who shall be selected alternately, on an annual basis, by Visterra or SIIL. The initial chairperson shall be selected by Visterra. The role of the chairperson shall be only to administer the
meetings of the JSC in a manner intended to ensure equal participation of each Party, and to ensure the prompt preparation of the minutes, but the chairperson shall have no additional powers or rights beyond those held by the other JSC
representatives. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 14

 (c) Meetings. The JSC shall meet at least once every six (6) months during the Term
unless the Parties mutually agree in writing to a different frequency for such meetings. The JSC shall hold its first meeting within sixty (60) days of the Effective Date. Either Party may also call a special meeting of the JSC (by
videoconference or teleconference) by at least ten (10) Business Days prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, and such Party
shall provide the JSC no later than five (5) Business Days prior to the special meeting with materials reasonably adequate to enable an informed decision. No later than ten (10) Business Days prior to any meeting of the JSC, the
chairperson of the JSC or a designate shall prepare and circulate an agenda for such meeting; provided, however, that either Party may propose additional topics to be included on such agenda, prior to such meeting. The JSC may meet in
person, by videoconference or by teleconference. Notwithstanding the foregoing, at least one (1) meeting per Calendar Year shall be in person unless the Parties mutually agree in writing to waive such requirement in lieu of a videoconference or
teleconference. In-person JSC meetings shall be held at a mutually agreeable location or alternating each meeting between a location selected by Visterra and by SIIL. Each Party shall bear the expense of its respective JSC members’
participation in JSC meetings. Translators at any meetings related to this Agreement shall be the responsibility of the Party requiring translation. All documents shared by one Party with the other Party will be provided in the form and language in
which the document is customarily maintained. Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present or participating in such meeting. The chairperson of the JSC or a designate shall be
responsible for preparing reasonably detailed written minutes of all JSC meetings that reflect, without limitation, material decisions made at such meetings. The JSC chairperson or a designate shall send draft meeting minutes to each member of the
JSC for review and approval within twenty (20) days after each JSC meeting. Such minutes shall be deemed approved unless one or more members of the JSC object to the accuracy of such minutes within twenty (20) days of receipt. Any
objections shall be resolved by the Parties within ten (10) days thereafter. If no resolution is reached in such ten (10) day period, then the Parties shall record, with the assistance of their legal counsel, the details of the dispute.

 (d) JSC Responsibilities. The JSC shall: 

(i) perform its designated roll regarding the Parties’ conduct under the Research and Development Plan and the Development of the
Product in the Field in the Licensed Territory by SIIL (provided that the JSC shall not be involved in the day-to-day management of the Development, Manufacture or Commercialization of the Product) as further set forth in this Agreement; 

(ii) prepare and approve annual or interim amendments to the Research and Development Plan; 

(iii) discuss and endeavor to resolve any disputes arising out of this Agreement; 

(iv) review and comment upon the Commercialization Plan presented to the JSC by SIIL in accordance with Section 6.1; 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 15

 (v) appointment of alliance managers; 

(vi) review and discuss the Publication Strategy for the Products; 

(vii) review and discuss proposed protocols for clinical trials to be conducted by SIIL in the Licensed Territory; and 

(viii) consider and act on such other matters that are specifically delegated to the JSC as specified in this Agreement. 

(e) JSC Actions. The JSC shall strive to seek consensus in its actions and decision making process. In the event of a disagreement
between the Visterra members and SIIL members of the JSC, either Party may refer the matter to one senior executive of each Party (i.e., the Chief Executive Officer of such Party or an executive of such Party who reports directly to the Chief
Executive Officer) for resolution. If such senior executives cannot resolve the matter within five (5) Business Days, then such senior executive of SIIL shall have the final decision making authority on such matter; provided that any
final determination made by such senior executive of SIIL shall be consistent with the terms of this Agreement and; further provided that SIIL shall not make any final decision with respect to (i) any amendments to the Research and
Development Plan that either (A) delay any activity by either Party provided for in such plan by more than six (6) months or (B) require Visterra to perform additional activities or commit additional resources to the performance of
activities under the Research and Development Plan or (ii) the approval of any protocol for a clinical trial proposed by SIIL if Visterra in good faith determines the performance of such clinical trial is reasonably likely to have an adverse
effect on the safety or wellbeing of patients. 
 (f) Termination of the JSC. 

(i) Disbanding of JSC. The Parties may disband the JSC upon mutual written agreement. 

(ii) Withdrawal from JSC. Visterra’s membership in the JSC shall be at its sole discretion, as a matter of right and not
obligation, for the sole purpose of participation in governance, decision-making and information exchange with respect to activities within the authority of the JSC. At any time, Visterra shall have the right to withdraw from membership or
participation in the JSC upon [**] days’ prior written notice to SIIL. Following Visterra’s withdrawal from membership or participation in the JSC, (A) the JSC shall be disbanded, (B) following disbandment of the JSC, all
decisions from and after such date which would have been submitted to the JSC for resolution under the Agreement had the JSC not been disbanded shall instead be submitted for resolution by the Chief Executive Officers of the Parties (or any senior
executive reporting directly to either Party’s Chief Executive Officer) and (C) each party shall have the right to continue to receive the information it would otherwise be entitled to receive under this Agreement. 

3.2. Scientific Exchanges. No less than [**], key scientific representatives from each Party (the “Key Scientific
Representatives”) shall meet in person, or by videoconference or by teleconference to discuss and exchange scientific findings and concerns relating to the Product. In-person meetings of the Key Scientific Representatives shall 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 16

 
be held at a mutually agreeable location or alternating each meeting between a location selected by Visterra and by SIIL. The Parties shall discuss and agree upon an agenda in advance for each
meeting of the Key Scientific Representatives and determine the appropriate representatives from each Party to be included in such meeting. Meetings of the Key Scientific Representatives shall be for information-exchanging and collaboration purposes
only and the Key Scientific Representatives shall have no decision-making authority. The Key Scientific Representatives shall continue to meet as provided in this Section 3.2 until [**] or until such time as otherwise mutually agreed upon by the
Parties. 
 3.3. Operational Meetings. No less than once per Calendar Quarter, key operational representatives from each Party (the
“Key Operational Representatives”) shall meet in person, or by videoconference or by teleconference to discuss key operational matters relating to the Development, Manufacture and Commercialization of the Product in the Visterra
Territory and Licensed Territory. In-person meetings of the Key Operational Representatives shall be held at a mutually agreeable location or alternating each meeting between a location selected by Visterra and by SIIL. The Parties shall discuss and
agree upon an agenda in advance for each meeting of the Key Operational Representatives and determine the appropriate representatives from each Party to be included in such meeting. Meetings of the Key Operational Representatives shall be for
information-exchanging and collaboration purposes only and the Key Operational Representatives shall have no decision-making authority. The Key Operational Representatives shall continue to meet as provided in this Section 3.3 until [**] or until
such time as otherwise mutually agreed upon by the Parties. 
 ARTICLE 4 

PRODUCT DEVELOPMENT 

4.1. Research and Development Plan. The initial plan for the research and Development of the Product in the Field in the Licensed
Territory, which includes a responsibility matrix allocating responsibility between the Parties, is attached hereto as Exhibit C (such plan, as amended from time to time as provided herein the “Research and Development
Plan”). The JSC shall oversee the Development of the Product in the Field in the Licensed Territory according to the Research and Development Plan. The Research and Development Plan shall provide generally for a budget for the internal
costs and out-of-pocket expenses to be incurred by Visterra in conducting activities under the Research and Development Plan and agreed upon by the Parties (including any reimbursements to be paid by either Party) and assignment of responsibilities
between the Parties for the various activities to be undertaken under the Research and Development Plan, including the following: [**]. During the Term, the JSC shall review the Research and Development Plan at least [**] and comment upon such
Research and Development Plan on an ongoing basis as necessary and the Parties will amend 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 17

 
such Research Plan to the extent necessary. The then-current Research and Development Plan shall at all times contain at least that level of detail and cover at least the same matters (to the
extent applicable) as the initial Research and Development Plan. 
 4.2. Development Responsibility. Unless specifically set forth in
the Research and Development Plan, SIIL shall be solely responsible for the conduct of all Development activities set forth in the Research and Development Plan. Visterra shall provide assistance to SIIL in an advisory role through the JSC and shall
conduct those activities for which it is specifically designated as the responsible Party in the Research and Development Plan. At each meeting of the JSC, each Party shall reasonably update the other Party on the status, progress and results of its
Development activities under the Research and Development Plan. 
 4.3. Diligence. Each Party shall use Commercially
Reasonable Efforts to conduct the Development activities assigned to it in the Research and Development Plan. In addition, SIIL shall: 

[**]. 
 Any failure by SIIL to achieve such
Development milestones within the relevant timeframes shall be deemed to be a breach of SIIL’s obligations under this Section 4.3, provided that SIIL’s failure to achieve such Development milestone to the extent such failure solely
results from Regulatory Authority inaction that is outside SIIL’s control (and not otherwise due to the action or inaction of SIIL, its Affiliate or anyone acting in its behalf) and solely for the duration of such inaction by such Regulatory
Authority, provided that SIIL continues to use Commercially Reasonable Efforts to meet such milestones accordingly. Without limiting the foregoing, SIIL shall use diligent efforts to Develop the Product in GAVI-Eligible Countries in the
Licensed Territory in a manner that is designed to enable availability and accessibility at reasonable cost. 
 4.4. Records. Each
Party shall maintain complete, current and accurate records of all work conducted by it under the Research and Development Plan, and all data and other Information resulting from such work. Such records shall fully and properly reflect all work done
and results achieved in the performance of the Development activities in good scientific manner 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 18

 
appropriate for regulatory purposes. Each Party shall have the right to review all records maintained by the other Party or its Affiliates or sublicensees at reasonable times, upon the reviewing
Party’s written request. 
 4.5. Development Costs. As between the Parties, SIIL shall bear all costs and out-of-pocket expenses
for the Development of the Product in the Field in the Licensed Territory as indicated in the Development Plan. SIIL shall reimburse Visterra for the costs of all employees and contractors dedicated to the performance of activities under the
Research and Development Plan (such costs to be reimbursed at a rate to be set forth in the Research and Development Plan) and the out-of-pocket expenses incurred by Visterra in conducting such activities. Visterra shall supply to SIIL all Licensed
Antibody and Product requested by SIIL, and SIIL shall reimburse Visterra for any Licensed Antibody or Product supplied to SIIL by Visterra, in each case, under and in accordance with the Research and Development Plan, at the Transfer Price. For
purposes of this Section 4.5, “Transfer Price” shall mean a price equal to the cost incurred by Visterra in Manufacturing the Licensed Antibody or Product (including the production of the active ingredient and the fill and finish of
the Product) supplied to SIIL under this Agreement and transporting such Product to the airport(s) where such Product will be exported to SIIL, including material costs, labor costs and overhead costs (including allocated facility costs, testing
costs and delivery costs); provided that if Visterra engages any Third Party contract manufacturer for the manufacture and supply of the Product, the Transfer Price shall be equal to Visterra’s costs actually incurred in such engagement,
the procurement of such Product from such Third Party and transporting such Product to such airport(s). Visterra shall provide a reasonably detailed invoice to SIIL for any amounts owed under this Section 4.5 after the end of each Calendar Quarter
in which such amounts were incurred. SIIL shall pay undisputed amounts set forth in each such invoice within forty-five (45) days after its receipt thereof. 

4.6. Annual Report. Within forty-five days after the end of each Calendar Year, SIIL shall furnish Visterra with a written report on
the progress of its efforts during the immediately preceding Calendar Year to Develop the Product in the Licensed Territory. The report shall also contain a discussion of intended efforts for the Calendar Year in which the report is submitted.

 ARTICLE 5 

REGULATORY MATTERS 

5.1. SIIL Regulatory Responsibilities. 

(a) SIIL shall own all Regulatory Filings, all pre-clinical data, clinical data generated from SIIL sponsored clinical trials and
Regulatory Approvals for the Product in the Licensed Territory, and shall be solely responsible for preparing any and all Regulatory Filings for the Product in the Licensed Territory at its sole expense, provided that Visterra will provide
SIIL with any Information or rights of reference in accordance with Section 2.3(a) as reasonably requested by SIIL in connection with the Licensed Antibody. The JSC shall review and comment on all such Regulatory Filings. SIIL shall keep Visterra
informed of regulatory developments specific to the Product throughout the Licensed Territory and shall reasonably consider any input from Visterra with respect to SIIL’s interactions with Regulatory Authorities in the Licensed Territory. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 19

 (b) SIIL shall ensure, at its sole expense, that the Development, Manufacture and
Commercialization of the Product in the Licensed Territory including any export or import of any Licensed Antibody or Product into or from the Licensed Territory is in compliance with all applicable Laws. 

(c) To the extent permitted by the applicable Regulatory Authority and as requested by Visterra, SIIL shall allow representatives of
Visterra to participate, at Visterra’s sole expense, in any scheduled conference calls and meetings between SIIL and any Regulatory Authority to the extent the call or meeting is specific to the Licensed Antibody. If Visterra elects not to
participate in such calls or meetings, SIIL shall provide Visterra with written summaries to the extent available of such calls and meetings as soon as practicable after they become available. 

(d) SIIL shall provide Visterra with copies of all final submissions and correspondence to and from all Regulatory Authorities relating
to the Product in the Field within thirty (30) days of submission or receipt, as applicable, and shall provide Visterra a summary of each significant submission (such as application for approval for clinical trials, Regulatory Approval and fast
track or orphan drug designation, the protocol for clinical trials and any modifications thereof) as soon as practicable but in any event within thirty (30) Business Days after such submission. 

5.2. Adverse Events. 

(a) Within [**], the Parties shall discuss in good faith and enter into a pharmacovigilance and adverse event reporting agreement
setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Product, such as safety data sharing, adverse events reporting and prescription events monitoring (the “Pharmacovigilance Agreement”). Such
Pharmacovigilance Agreement shall govern the global pharmacovigilance procedures to be agreed upon by SIIL, Visterra and the commercial partners of each Party. 

(b) Prior to the execution of such Pharmacovigilance Agreement, the Parties agree to coordinate the pharmacovigilance procedures in
connection with the Development of the Product, SIIL shall submit to Visterra all SIIL safety information and reporting in a manner that, to the extent practicable, meets the reporting requirements in the Visterra Territory for such information and
Visterra shall submit to SIIL all of Visterra’s (including its sublicensees’ and Affiliate’s) safety information and reporting in a manner that meets the reporting requirements in the Licensed Territory. SIIL shall own all the safety
information, including any safety databases for the Product, generated by or on behalf of SIIL in the Licensed Territory. Each Party shall notify the other Party within twenty-four (24) hours of such Party’s learning of any Serious Adverse
Events that is attributed to or potentially attributable to the use of the Product. Each Party shall also provide the other Party, on an annual basis and more frequently as reasonably requested by the other Party, a summary report of Adverse Events,
as well as those Serious Adverse Events that are not attributable to the use of the Product. 
 (c) After the execution of the
Pharmacovigilance Agreement, the Parties shall comply with the Pharmacovigilance Agreement with respect to all aspects of pharmacovigilance 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 20

 
activities with respect to the Product, and Section 5.2(b) shall be of no further effect. 

5.3. No Harmful Actions. If either Party believes that the other Party, as the case may be, is taking or intends to take any action
with respect to the Product that could reasonably be expected to have a material adverse impact upon the regulatory status of the Product in the Visterra Territory or the Licensed Territory, such Party shall bring the matter to the attention of the
other Party. Without limiting the foregoing, unless the Parties otherwise agree, a Party shall not communicate concerning the Product with any Regulatory Authority having jurisdiction in the other Party’s territory, unless so ordered by such
Regulatory Authority or such communication is required by applicable Law. Such communications shall be promptly disclosed by the communicating Party to the other Party. 

5.4. Notification of Threatened Action. Each Party shall notify the other Party as soon as practicable of any notice from a Regulatory
Authority having jurisdiction in its territory, that relates to an impending action or inspection, and that would reasonably be expected to adversely affect the safety or efficacy claims of the Product or the continued marketing of the Product. Upon
receipt of such information, the Parties shall consult with each other in an effort to agree an appropriate response. 
 5.5.
Remedial Actions. Each Party shall, and shall ensure that its Affiliates shall, notify the other Party immediately, and promptly confirm such notice in writing, if it obtains information indicating that the Product may be subject to any recall
or withdrawal with respect to a Product taken by virtue of applicable Law in the Licensed Territory (a “Remedial Action”). The Parties shall assist each other in gathering and evaluating such information as is necessary to determine
the necessity of conducting a Remedial Action, provided that SIIL shall have sole and final decision-making authority as to the initiation and scope of any Remedial Action in the Licensed Territory. To the extent required by applicable Law,
SIIL shall, and shall ensure that its Affiliates shall, maintain or have maintained adequate records to permit the Parties to trace the Manufacture of the Product and the distribution and, to the extent feasible, the use of the Product. If SIIL
determines that any Remedial Action with respect to the Product in the Field in the Licensed Territory should be commenced or Remedial Action is required by any Regulatory Authority having jurisdiction over the matter, SIIL shall control and
coordinate all efforts necessary to conduct such Remedial Action. For clarity, as between the Parties, Visterra shall have sole discretion with respect to any matters relating to any Remedial Action in the Visterra Territory. The cost and expense of
a Remedial Action arising from the Development, Manufacture or Commercialization of the Product in the Field in the Licensed Territory shall be borne solely by SIIL. Except as may be provided in a Supply Agreement, the cost and expense of both
Parties in respect of a Remedial Action arising from the Development, Manufacture or Commercialization of the Product in the Visterra Territory shall be borne solely by Visterra. 

ARTICLE 6 

COMMERCIALIZATION 

6.1. Overview of Commercialization in the Licensed Territory. SIIL shall be solely responsible for all aspects of the Commercialization
of the Product in the Field in the Licensed Territory, in compliance with all applicable Laws in accordance with a commercialization plan to  

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 21

 
be prepared by SIIL and provided to JSC for its review and comment prior to the First Commercial Sale of the Product in the Licensed Territory (the “Commercialization Plan”).
Such Commercialization Plan shall include, to the extent permitted by applicable Law, the activities to be conducted and the overall timelines therefor in preparation for the launch of the Product and after such Product launch in the respective
countries and marketing materials, which shall be updated on [**] basis during the [**]-month period prior to the First Commercial Sale of the Product and thereafter on [**] basis by SIIL and provided to the JSC for its review and comment. SIIL
shall book sales for the Product in the Licensed Territory and shall be responsible for all order processing, invoicing, collection, distribution, inventory, and returns necessary in connection therewith. 

6.2. SIIL Performance. 

(a) SIIL shall use Commercially Reasonable Efforts to Commercialize the Product in the Licensed Territory. Without limiting the
foregoing, SIIL shall use diligent efforts to Commercialize the Product in GAVI-Eligible Countries in the Licensed Territory in a manner that is designed to enable availability and accessibility at reasonable price. 

(b) If a Product has been approved for commercial sale in any country (either in the Licensed Territory or Visterra Territory), but has
not been approved for commercial sale in one or more GAVI-Eligible Countries in the Licensed Territory, the Parties shall promptly meet to discuss, and SIIL shall commit to Visterra, in writing with mutually agreed upon timelines (such timelines to
be enforceable under this Agreement), that it or an Affiliate shall, (A) promptly apply for approval for commercial sale of such Product in such GAVI-Eligible Countries in the Licensed Territory, and (B) promptly after receiving approval,
begin and continue to sell such Product in such GAVI-Eligible Countries in Licensed Territory at reasonably affordable prices in sufficient volume to meet market demand in such countries. 

6.3. Trademark. SIIL shall have the sole and exclusive right to brand the Product in the Licensed Territory using names, trademarks and
trade dress it determines appropriate for the Product, which may vary by country or within a country (“Product Marks”). SIIL shall own all rights and goodwill in the Product Marks and register and maintain the Product Marks in the
countries and regions it determines reasonably necessary. 
 6.4. Reporting. 

(a) First Commercial Sale. SIIL shall report to Visterra the date of First Commercial Sale of a Product within [**] days of occurrence
in each country in the Licensed Territory. 
 (b) Quarterly Reports. Within thirty (30) days after the end of each
Calendar Quarter following the First Commercial Sale of the Product in the Licensed Territory, SIIL shall present a written report to Visterra summarizing SIIL’s Commercialization activities with respect to the Product in the Licensed Territory
(including any GAVI-Eligible Countries in the Licensed Territory) pursuant to this Agreement, which content of such reports shall include, at a minimum, all information required under the MIT Agreement, applicable grant funding documentation, the
Commercialization Plan and as otherwise reasonably required by Visterra to 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 22

 
facilitate Visterra’s reporting obligations to upstream licensors. 
 ARTICLE 7

 MANUFACTURING 

7.1. Overview. Unless to the extent License Antibody and Product is to be supplied by, or on behalf of, Visterra hereunder, SIIL shall
be responsible for the Manufacture of all Licensed Antibody and Product necessary for the Development and Commercialization of the Product in the Licensed Territory. Manufacture of all Licensed Antibody and Product for the Licensed Territory shall
be in accordance with applicable Good Manufacturing Practice, other applicable Laws and specifications of the Product agreed by the Parties. 

7.2. Visterra Territory Supply Agreement. Following the Effective Date, the Parties shall in good faith negotiate an agreement pursuant
to which SIIL would Manufacture and supply Licensed Antibody and Product to Visterra for Commercialization in the [**] (a “Supply Agreement”). The Supply Agreement shall contain customary and commercially reasonable terms, including
the right for Visterra to engage, validate and maintain, at its sole cost and expense, Third Parties as alternate or backup suppliers of the Product for an agreed upon percentage of Visterra’s requirements. If the Parties have not entered into
the Supply Agreement by the date that is [**], then neither Party shall have any further obligation to negotiate the Supply Agreement and Visterra shall be free to enter into an agreement with a Third Party for the Manufacture and supply of the
Licensed Antibody and Product for Commercialization in the [**]. Prior to such date, Visterra shall not [**]. 
 ARTICLE 8 

FINANCIAL PROVISIONS 

8.1. Upfront Fee. Within ten (10) Business Days after the Effective Date, SIIL shall pay to Visterra a one-time, non-refundable
and non-creditable upfront fee of Five Million US Dollars ($5,000,000). 
 8.2. Milestone Payments. SIIL shall make the
following one-time, non-refundable and non-creditable milestone payments to Visterra within thirty (30) days after the first achievement of each milestone event for a Product as set forth in this Section 8.2 by SIIL or its Affiliates (or with
respect to Regulatory Milestone #2 set forth below, by Visterra or its Affiliates, licensees, collaborators or contractors). Each milestone payment by SIIL to Visterra hereunder shall be payable only once, regardless of the number of times achieved
by the Products. For clarity, it is possible for both sales milestones to be achieved in the same four (4) consecutive Calendar Quarters. If the regulatory milestone set forth in item 2 of the below table is achieved with respect to a Product
prior to the achievement of the regulatory milestone set forth in item 1 of the below table for such Product, then the milestone payments due and payable  

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 23

 
for the earlier milestone shall be due and payable simultaneously with the payment for achievement of the later milestone event. 

 

			
	 Milestone Event
	  	 Milestone Payment

	 Regulatory Milestones

	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
		  	
	
	 Sales Milestones

	The aggregate Net Sales of all Products in the Licensed Territory during four (4) consecutive Calendar Quarters during the Term equal or exceed $[**]	  	[**]
		
	The aggregate Net Sales of all Products in the Licensed Territory during four (4) consecutive Calendar Quarters during the Term equal or exceed $[**]	  	[**]

 8.3. Royalties.  

(a) Royalty Rates. SIIL shall pay to Visterra non-refundable, non-creditable royalties on annual Net Sales of Products in the Licensed
Territory, as follows: 
  

					
	 Aggregate Annual Net Sales of all Products in the Licensed Territory for a Particular Calendar Year
	  	Royalty Rate	 
	 For that portion of aggregate annual Net Sales of Products in the Licensed Territory less than $[**]
	  	 	[	**] 
	 For that portion of aggregate annual Net Sales of Products in the Licensed Territory equal to or greater than $[**] but less than
$[**]
	  	 	[	**] 
	 For that portion of aggregate annual Net Sales of Products in the Licensed Territory equal to or greater than $[**]
	  	 	[	**] 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 24

 (b) Royalty Term. Royalties under Section 8.3(a) shall be due, on a country-by-country
basis and Product-by-Product basis, during the period beginning on the First Commercial Sale of the Product in such country, and ending upon the later of (i) the expiration of the last-to-expire Valid Claim in the country covering the Product
sold in such country; (ii) the expiration of Regulatory Exclusivity covering the Product sold in such country, where such Regulatory Exclusivity is provided under the law; and (iii) the tenth
(10th) anniversary after the First Commercial Sale of the Product in such country (the “Royalty Term”). 

(c) Know-How Royalty. If a Product is generating Net Sales in a country in the Licensed Territory during the Royalty Term at a time
when there is no Valid Claim covering the Product in such country, then the royalty rates applicable to Net Sales of such Product during the Royalty Term in such country pursuant to Section 8.3(a) shall be reduced by [**] percent ([**]%).

 (d) Third Party Licenses. Visterra covenants that it takes full responsibility for the timely payment of all payments due and
payable under the MIT Agreement, including any in relation to activities contemplated by this Agreement. If SIIL determines, on the advice of patent counsel, that it is necessary to obtain one or more licenses under Patents or Know-how of Third
Parties in order to make, have made, use, sell, have sold, offer for sale or import a Product in a country in the Licensed Territory (“Third Party Patent Licenses”), [**] percent ([**]%) of the royalties actually paid to Third
Parties under such Third Party Patent Licenses by SIIL for the sale of such Product in such country for a Calendar Quarter shall be creditable against the royalty payments due Visterra by SIIL with respect to Net Sales of such Product in such
country for such Calendar Quarter; provided, however, that in no event shall the royalties otherwise owed by SIIL to Visterra for such Calendar Quarter be reduced by more than [**] percent ([**]%) as a result of any and all such
offsets in the aggregate. Any portion of the royalties paid to Third Parties under such Third Party Patent Licenses with respect to such Product in such country that SIIL would, but for the foregoing limitation on royalty reductions, be entitled to
deduct under this Section 8.3(d) shall be carried over and applied against royalties payable to Visterra in respect of such Product in subsequent Calendar Quarters until the full deduction is taken, subject to the foregoing proviso. 

(e) Royalty Payments and Reports. Within thirty (30) days after the end of each Calendar Quarter, SIIL shall deliver to Visterra a
report containing the following information for the just-ended Calendar Quarter: (i) the number of Products sold or distributed by SIIL or its Affiliates to independent Third Parties in each country; (ii) the gross sales associated with
each Product sold by SIIL or its Affiliates; (iii) a calculation of Net Sales of Products that are sold by SIIL or its Affiliates in each country, including a listing of applicable deductions; and (iv) a calculation of payments due to
Visterra in Dollars with respect to sales of Products during the relevant Calendar Quarter, together with the exchange rates used for conversion, the current Product price lists as well as any projected price adjustments for Products during the
subsequent Calendar Quarter. Simultaneously with the delivery of such report, SIIL shall remit to Visterra any payment due for the applicable Calendar Quarter. If no royalties are due to Visterra for such reporting period, the report shall so
state. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 25

 8.4. Foreign Exchange. Net Sales will be made in both Dollars and other currencies. To the
extent Net Sales are made in currencies other than the Dollar, the amount payable to Visterra in respect of such Net Sales shall be converted to Dollars on the date of remittance at the foreign exchange rate determined by Reserve Bank Of India. All
payments from a Party to the other Party shall be made by wire transfer in immediately available funds in Dollars to the credit of such bank account as may be designated by the other Party in this Agreement or in writing to such Party. Any payment
which falls due on a date which is not a Business Day may be made on the next succeeding Business Day. When conversion of payments from any foreign currency is required to be undertaken by a Party, the Dollar equivalent shall be calculated using
such Party’s then-current standard exchange rate conversion methodology as applied in its external reporting, which shall be in accordance with applicable accounting standards. 

8.5. Payment Method; Late Payments. All payments due to Visterra hereunder shall be made in Dollars by wire transfer of immediately
available funds into an account designated by Visterra. If Visterra does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to Visterra until the date of payment at the per
annum rate of [**] percent ([**]%) over the then-current prime rate reported by the Federal Reserve Bank of Boston on the last Business Day of the relevant reporting period or the maximum rate allowable by applicable Law, whichever is lower.

 8.6. Records; Audits. SIIL shall maintain complete and accurate records in sufficient detail to permit Visterra to confirm the
accuracy of the calculation of royalty payments under this Agreement. Upon reasonable prior notice, such records shall be available during regular business hours for a period of [**] years from the end of the Calendar Year to which they pertain for
examination at the expense of Visterra, and not more often than [**], by an independent certified public accountant selected by Visterra and reasonably acceptable to SIIL for the sole purpose of verifying the accuracy of the financial reports
furnished by SIIL pursuant to this Agreement. Any such auditor shall not disclose to Visterra SIIL’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by SIIL
or the amount of payments due by SIIL under this Agreement. Any amounts shown to be owed but unpaid shall be paid within thirty (30) days from the receipt by SIIL of the accountant’s report, plus interest (as set forth in Section 8.5) from
the original due date. Visterra shall bear the full cost of such audit unless such audit discloses an underpayment by SIIL of more than [**] percent ([**]%) of the amount due, in which case SIIL shall bear the full cost of such audit. SIIL shall
promptly remit to Visterra any amounts shown to be owing pursuant to any audit under this Section 8.6. 
 8.7. Taxes. 

(a) Taxes on Income. Each Party shall be solely responsible for the payment of all Taxes imposed on its share of income arising under
this Agreement or directly or indirectly from the efforts of the Parties under this Agreement. The royalties, milestones and other amounts payable by SIIL to Visterra pursuant to this Agreement shall not be reduced on account of any Taxes except to
the extent that any such reduction or withholding is required by applicable Law in effect at the time of payment. 
 (b) Indirect
Taxes. The Parties shall cooperate in accordance with applicable  

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 26

 Law to minimize indirect taxes (such as service tax levy, value added tax, sales tax, consumption tax and
other similar taxes (“Indirect Taxes”)) in connection with this Agreement. Notwithstanding anything contained in Section 8.7(a), this Section 8.7(b) shall apply with respect to Indirect Taxes. All payments required to be
paid to Visterra hereunder are exclusive of Indirect Taxes as may be applicable under Indian Laws. If any Indirect Taxes are chargeable in respect of any payments as may be applicable under Indian Laws, SIIL shall pay such Indirect Taxes in addition
to the amounts agreed under this Agreement to Visterra at the applicable rate in respect of any such payments following the receipt, where applicable, of an Indirect Taxes invoice in the appropriate form issued by Visterra in respect of those
payments. The Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes. For clarity, under this
Section 8.7(b), if Visterra is required by Law to pay any Indirect Taxes under relevant Indian Tax Laws, then SIIL will reimburse Visterra for any Indirect Taxes required to be paid by Visterra accordingly. 

(c) Tax Cooperation. To the extent SIIL is required to deduct and withhold Taxes on any payment to Visterra, SIIL shall pay the amounts
of such Taxes to the proper taxing authority in a timely manner and promptly transmit to Visterra an official tax certificate or other evidence of such withholding sufficient to enable Visterra to claim such payment of Taxes. Visterra shall provide
SIIL any tax forms and documents, such as Permanent Account Numbers issued by Indian tax authorities and tax residency certificates, that may be reasonably necessary in order for SIIL to not withhold tax or to withhold tax at a reduced rate under an
applicable bilateral income tax treaty. Visterra shall use reasonable efforts to provide any such tax forms to SIIL at least thirty (30) days prior to the due date for any payment for which Visterra desires that SIIL applies a reduced
withholding rate. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Law, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this
Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax. For clarity, subject to the terms of this Agreement, SIIL and its Affiliates bear no responsibility for the recovery by or credit to
Visterra of any amounts reasonably and properly withheld by SIIL (excluding any act/omission by SIIL resulting in fines, penalties or other liability imposed by the applicable government authorities). 

ARTICLE 9 
 INTELLECTUAL
PROPERTY 
 9.1. Ownership of Inventions. Each Party shall own any inventions made solely by its own employees, agents, or
independent contractors in the course of conducting its activities under this Agreement, together with all intellectual property rights therein (“Sole Inventions”). The Parties shall jointly own any inventions that are made jointly
by employees, agents, or independent contractors of each Party in the course of performing activities under this Agreement, together with all intellectual property rights therein (“Joint Inventions”). Inventorship shall be
determined in accordance with U.S. patent laws. All Patents claiming patentable, jointly owned Joint Inventions shall be referred to herein as “Joint Patents.” Except to the extent otherwise set forth in this Agreement, each Party
shall be entitled to practice and  

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 27

 
exploit (including through the grant of licenses and covenants not to sue) the Joint Inventions without a duty of accounting or seeking consent from the other Party. 

9.2. Disclosure of Inventions. Each Party shall promptly disclose to the other Party any invention disclosures, or other similar
documents, submitted to it by its employees, agents or independent contractors describing inventions that are either Sole Inventions or Joint Inventions. Further, each Party shall promptly disclose to the other Party all Information relating to
Joint Inventions to the extent necessary for the preparation, filing and maintenance of any Joint Patent with respect to such Joint Invention. Each Party shall ensure that its and its Affiliates’ employees, officers, and consultants engaged in
the Development or Commercialization of the Product have executed agreements or have existing obligations under applicable Law requiring assignment to such Party or its Affiliate, as applicable, of all inventions made during the course of and as the
result of their association with such Party/Affiliate and obligating the individual to maintain as confidential such Party’s Confidential Information as well as confidential information of other parties (including the other Party and its
Affiliates) which such individual may receive, to the extent required to support such Party’s obligations under this Agreement. 

9.3. Prosecution of Patents. 

(a) Visterra Patents. 

(i) Subject to Sections 9.3(a)(ii) and 9.3(a)(iii) and below, Visterra shall have the sole right to prepare, file, prosecute and
maintain Visterra Patents and Joint Patents (collectively, the “Visterra Prosecuted Patents”). Visterra shall provide SIIL reasonable opportunity to review and comment on such prosecution efforts regarding such Visterra Prosecuted
Patents in the Licensed Territory. Visterra shall provide SIIL with a copy of material communications from any patent authority in the Licensed Territory regarding such Visterra Prosecuted Patents, and shall provide drafts of any material filings or
responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses for SIIL’s review and comment. Visterra shall reasonably consider such comments by SIIL and shall include them unless
Visterra has a reasonable objection in connection with the prosecution of Visterra Prosecuted Patents in the Licensed Territory. 

(ii) The costs and expenses incurred after December 17, 2014, by Visterra in connection with the preparation, filing, prosecution
and maintenance of Visterra Patents and Joint Patents under Section 9.3(a)(i) shall be allocated between the Parties as follows: (A) SIIL shall reimburse Visterra for all actual out-of-pocket costs (including reasonable attorneys’ fees)
incurred by Visterra in connection with the preparation, filing, prosecution and maintenance of the Visterra Prosecuted Patents in the Licensed Territory and (B) Visterra shall bear all other fees and expenses. 

(iii) If Visterra wishes to cease the prosecution or maintenance of any Visterra Prosecuted Patents in the Licensed Territory, it
shall notify SIIL to that effect in writing, and SIIL may, at its discretion, assume the rights to the prosecution or maintenance of such Visterra Prosecuted Patents, at SIIL’s sole expense, by informing Visterra in writing within sixty
(60) days after receiving such notification from Visterra. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 28

 (iv) Except with respect to commercially reasonable actions/inactions taken by Visterra
with respect to the filing and maintenance of Joint Patents, if Visterra does not otherwise initiate actions for filing a Joint Patent in the Licensed Territory within [**] days of communication by SIIL or refuses to file the application for grant
of a patent for any other reasons, then SIIL may initiate actions at its own cost to file a patent application, in which case, provided that such patent application/Joint Patent does not contain claims specific to the Product, such patent
application/Joint Patent will then be a SIIL Patent solely owned and controlled by SIIL. 
 (b) SIIL Patents. SIIL shall have the
sole right to prepare, file, prosecute and maintain SIIL Patents at SIIL’s costs and expense. If SIIL decides to cease the prosecution or maintenance of any SIIL Patents (except to the extent included within the SIIL Manufacturing Technology),
it shall notify Visterra in writing sufficiently in advance. Visterra may, at its discretion, assume the rights to the prosecution or maintenance of such SIIL Patents, at Visterra’s sole expense by informing SIIL in writing within sixty
(60) days after receiving such notification from SIIL. 
 (c) Cooperation in Prosecution. Each Party shall provide the
other Party all reasonable assistance and cooperation with respect to the assumption of the prosecution and maintenance of Visterra Prosecuted Patents by SIIL or the assumption of the prosecution and maintenance of SIIL Patents by Visterra pursuant
to Sections 9.3(a) or 9.3(b), as the case may be, including providing any documents necessary to conduct such activities. 
 9.4.
Infringement of Patents by Third Parties. 
 (a) Notification. Each Party shall promptly notify the other Party in writing of any
existing or threatened infringement of the Visterra Patents or Joint Patents through the Development or Commercialization of a Product in the Field in the Licensed Territory by a Third Party, of which such Party becomes aware, including any
certification or the like in the Licensed Territory similar to “patent certification” of 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) and of any declaratory judgment, opposition, revocation, or similar action alleging the
invalidity, unenforceability or non-infringement of any of the Visterra Patents (collectively “Product Infringement”). 

(b) Product Infringement. 

(i) For any Product Infringement in the Field in the Licensed Territory, each Party shall share with the other Party all Information
available to it regarding such existing or threatened infringement. SIIL shall have the first right, but not the obligation, to bring an appropriate suit or other action against any person or entity engaged in such Product Infringement, subject to
Section 9.4(b)(ii) through 9.4(b)(v). If SIIL fails to institute and prosecute an action or proceeding to abate such Product Infringement within a period of [**] days after the first notice under Section 9.4(a), then Visterra shall have the right,
but not the obligation to, commence a suit or take action to enforce the applicable Visterra Patent or Joint Patent against such Third Party perpetrating such Product Infringement in the Licensed Territory at its own cost and expense. In this case,
SIIL shall take appropriate actions, if any, in order to enable Visterra to commence a suit or take the actions set forth in the preceding sentence. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 29

 (ii) Each Party shall provide to the Party enforcing the Visterra Patent or Joint Patent
under this Section 9.4(b) reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including joining such action as a party plaintiff if required by applicable Law to pursue such action. If any suit brought by
SIIL must be brought in MIT’s name or MIT is joined as a party-plaintiff to any suit brought by SIIL, SIIL shall hold MIT harmless from and indemnify MIT against any costs, expenses or liability that MIT incurs in connection with such action on
Visterra’s behalf. The enforcing Party with respect to any action under this Section 9.4(b) shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s
comments on any such efforts, and shall seek consent of the other Party in any important aspects of such enforcement including determination of litigation strategy, filing of important papers to the competent court, which shall not be unreasonably
withheld or delayed. If SIIL brings any action under this Section 9.4(b) involving existing or threatened infringement of the MIT Patents, SIIL shall consult with Visterra to seek input from MIT and shall consider the views of MIT regarding the
advisability of the proposed action and its effect on the public interest, including without limitation, the availability and accessibility of Products at a reasonable price to people most in need within GAVI-Eligible Countries. Visterra shall
cooperate with SIIL in facilitating all correspondence with MIT required under this Section 9.4(b)(ii). 
 (iii) If SIIL
commences a Product Infringement action, it shall bear all internal and out-of-pocket costs and expenses incurred by both Parties in connection with such action. In the event that Visterra commences a Product Infringement action, it shall bear all
internal and out-of-pocket costs and expenses incurred by both Parties in connection with such action. 
 (iv) The Party not
bringing an action with respect to Product Infringement under this Section 9.4(b) shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with
the Party bringing such action. 
 (v) Notwithstanding anything to the contrary contained herein, MIT shall have the first
right to defend any Product Infringement involving a Patent Challenge with respect to the MIT Patents as set forth in Section 7.3 of the MIT Agreement, and Visterra shall consult with and keep SIIL reasonably informed with respect thereto.

 (c) Infringement Other Than a Product Infringement. For any and all infringement of any Visterra Patent or Joint Patent other
than a Product Infringement in the Field in the Licensed Territory, as between the Parties, Visterra shall have the sole and exclusive right to bring an appropriate suit or other action against any person or entity engaged in such other
infringement, in its sole discretion, and as between the Parties shall bear all related expenses and retain all related recoveries. 

(d) Settlement. SIIL shall not settle any claim, suit or action that it brought under this Section 9.4 involving Visterra Patents or
Joint Patents in any manner that would negatively impact such Visterra Patents or Joint Patents or that would limit or restrict the ability of Visterra to Develop, make, import, use, offer for sale, sell or otherwise Commercialize Products anywhere
in the Visterra Territory without the prior written consent of Visterra, which 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 30

 
consent shall not be unreasonably withheld, conditioned or delayed. Nothing in this Article 9 shall require Visterra to consent to any settlement that is reasonably anticipated by Visterra to
have a substantially adverse impact upon any Visterra Patent or Joint Patent in the Visterra Territory, or to the Development, Manufacture, Commercialization, use, importation, offer for sale or sale of the Product in the Visterra Territory. SIIL
shall not enter into any settlement, consent judgment, or other voluntary final disposition of any infringement action involving existing or threatened infringement of the MIT Patents without the prior written consent of MIT. Visterra shall
cooperate with SIIL in facilitating all correspondence with MIT required under this Section 9.4(d). 
 (e) Allocation of Recoveries.
If either Party recovers monetary damages from any Third Party in a suit or action brought for a Product Infringement, such recovery shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation (including,
for this purpose, a reasonable allocation of expenses of internal counsel and any amounts owed to MIT for offsets under Section 7.4 of the MIT Agreement), and any remaining amounts shall be retained by the Party bringing suit, provided
that, if SIIL is the Party bringing suit, such remaining amounts shall be included in the Net Sales subject to the royalty payment by SIIL to Visterra under Section 8.3 and; provided, further, that to the extent any such recoveries
represent special or punitive damages recovered in a suit or action brought for infringement of the MIT Patents, [**] percent ([**]%) of such special or punitive damages shall be paid to MIT. 

9.5. Infringement of Third Party Rights in the Licensed Territory. If any Product used or sold by SIIL or its Affiliates becomes the
subject of a Third Party’s claim or assertion of infringement of a Patent granted by a jurisdiction within the Licensed Territory, SIIL shall promptly notify Visterra thereof (an “Infringement Claim”). In the case of any
Infringement Claim, the Parties shall promptly, and within fifteen (15) days after written notice from either Party to the other thereof, discuss which Party shall control the response to such Infringement Claim, and if the Parties do not
mutually agree upon which Party shall control, the Visterra shall control the defense and response to such Infringement Claim. Upon the request of the Party controlling the response to the Infringement Claim, the other Party shall reasonably
cooperate with the controlling Party in the reasonable defense of such Infringement Claim. The other Party shall have the right to consult with the controlling Party concerning any Infringement Claim and to participate in and be represented by
independent counsel in any associated litigation. If the Infringement Claim is brought against both Parties, then each Party shall have the right to defend against the Infringement Claim. 

9.6. Marking of Products. To the extent commercially feasible and consistent with prevailing business practices, SIIL shall mark, and
shall cause its Affiliates to mark, all Products that are Manufactured or sold under this Agreement with the number of each issued patent under the Visterra Patents that applies to such Product. 

ARTICLE 10 

REPRESENTATIONS AND WARRANTIES; COVENANTS 

10.1. Mutual Representations and Warranties. Each Party hereby represents, warrants, and covenants (as applicable) to the other Party
as follows: 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 31

 (a) Corporate Existence and Power. It is a company or corporation duly organized, validly
existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being
conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder. 
 (b)
Authority and Binding Agreement. As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate
action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a
legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms. 
 (c) No
Conflict; Covenant. It is not a party to any agreement that would materially prevent it from granting the rights granted to the other Party under this Agreement or performing its obligations under this Agreement. 

(d) No Debarment. In the course of the Development of the Product, neither Party shall use, during the Term, any employee or consultant
who has been debarred by any Regulatory Authority, or, to the best of such Party’s knowledge, is the subject of debarment proceedings by a Regulatory Authority. 

10.2. Additional Representations and Warranties of Visterra. Visterra represents and warrants to SIIL as of the Effective Date as
follows: 
 (a) Subject to the rights of the U.S. federal government with respect to any government-funded invention claimed
in any MIT Patent as set forth in 35 U.S.C. §§ 201-211, and the regulations promulgated thereunder, Visterra has the right under the Visterra Technology to grant the licenses to SIIL as purported to be granted pursuant to this
Agreement. 
 (b) The MIT Agreement is in full force and effect as modified or amended prior to the Effective Date, and
Visterra has provided to SIIL true and complete copies of such agreement, and any redacted portions thereof are not material to SIIL’s decision to enter into or assert its rights and perform its obligation under this Agreement. Neither Visterra
nor, to Visterra’s knowledge, MIT is in default with respect to a material obligation under, and neither Visterra nor MIT has claimed or, to Visterra’s knowledge, has grounds upon which to claim, that the other party is in default with
respect to a material obligation under the MIT Agreement. 
 (c) No Third Party other than MIT has granted Visterra a license
to Patents or Information that are not Controlled by Visterra or its Affiliates but that would, if Controlled by Visterra or its Affiliates, be within the definition of Visterra Patents or Visterra Know-How. 

(d) Visterra owns or Controls all of the Visterra Patents and Visterra Know-How free from encumbrances and is listed in the records of
the appropriate governmental authorities as the owner of record or licensee for each registration, grant and application included in the Visterra Patents. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 32

 (e) (i) Visterra has, with respect to Patents or Know-How owned by it, obtained from all
individuals who participated in any respect in the invention or authorship of any such Patents or Know-How, effective assignments of all ownership rights of such individuals in such Patents or Know-How, and (ii) to the knowledge of Visterra,
with respect to Patents or Know-How licensed to Visterra under the MIT Agreement, MIT has obtained from all individuals who participated in any respect in the invention or authorship of any such Patents or Know-How, effective assignments of all
ownership rights of such individuals in such Patents or Know-How, in the case of each of (i) and (ii), to the extent that any such Patents or Know-How would constitute Visterra Patents or Visterra Know-How, as applicable, if Controlled by
Visterra, either pursuant to written agreement or by operation of law. 
 (f) All of Visterra’s and its Affiliates’
employees, officers, and consultants engaged in the Development or Commercialization of the Product have executed agreements or have existing obligations under applicable Law requiring assignment to Visterra or its Affiliates, as applicable, of all
inventions made during the course of and as the result of their association with Visterra and obligating the individual to maintain as confidential Visterra’s Confidential Information as well as confidential information of other parties
(including SIIL and its Affiliates) which such individual may receive, to the extent required to support Visterra’s obligations under this Agreement. 

(g) All application, registration, maintenance and renewal fees in respect of Visterra Patents as of the Effective Date have been, with
respect to Visterra Patents owned by Visterra and, to Visterra’s knowledge, with respect to Visterra Patents licensed to Visterra, paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of
maintaining Visterra Patents. 
 (h) Other than the MIT Agreement, there are no agreements or arrangements to which Visterra
or any of its Affiliates is a party relating to the Licensed Antibody, Product, Visterra Patents, or Visterra Know-How that would limit the rights granted to SIIL under this Agreement or that restrict or will result in a restriction on the
Parties’ ability to Develop, Manufacture, use or Commercialize the Licensed Antibody or Product in the Field in the Territory; 

(i) Neither Visterra nor any of its Affiliates, nor any of its or their respective officers, employees, representatives or agents has
made an untrue statement of material fact or fraudulent statement to the United States Food and Drug Administration (the “FDA”) or any other Regulatory Authority with respect to the Development of the Licensed Antibody, failed to
disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority with respect to the Development of the Licensed Antibody, or committed an act, made a statement, or failed to make a statement with respect to the
Development of the Licensed Antibody. 
 (j) In the course of the Development of the Licensed Antibody, neither Visterra nor
any of its Affiliates has used prior to the Effective Date any employee, agent or independent contractor who has been debarred or excluded from participation in government healthcare programs by any Regulatory Authority, or, to Visterra’s
knowledge, is the subject of 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 33

 
debarment or exclusion proceedings by a Regulatory Authority or has been convicted pursuant to § 306 of the Food, Drug, and Cosmetic Act. 

(k) Visterra has not received any written notice from any Third Party asserting or alleging that any research or Development of any
Product by Visterra prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third Party. 

(l) To Visterra’s knowledge, the Development, Manufacture and Commercialization of the Product in the Licensed Territory pursuant
to this Agreement will not infringe any Third Party’s valid intellectual property rights. 
 (m) There are no actual,
pending, alleged or threatened adverse actions, suits, claims, interferences or formal governmental investigations involving the Product or the Visterra Technology relating to the Product by or against Visterra or any of its Affiliates or licensees
in or before any court, Regulatory Authority or other governmental authority. 
 10.3. Representation and Warranty of SIIL.
SIIL represents and warrants to Visterra as of the Effective Date, and covenants thereafter, that all of SIIL’s and its Affiliates’ employees, officers, and consultants engaged in the Development or Commercialization of the Product have
executed agreements or have existing obligations under applicable Law requiring assignment to SIIL or its Affiliates, as applicable, of all inventions made during the course of and as the result of their association with SIIL and obligating the
individual to maintain as confidential SIIL’s Confidential Information as well as confidential information of other parties (including Visterra and its Affiliates) which such individual may receive, to the extent required to support SIIL’s
obligations under this Agreement. 
 10.4. Covenants of Visterra. 

(a) During the Term, Visterra shall (i) maintain the MIT Agreement in full force and effect; (ii) promptly provide SIIL with
a party’s notice of any default under the MIT Agreement; (iii) to the extent within Visterra’s reasonable control, not take any action, fail to take any action or allow any event to occur that would give MIT the right to terminate the
MIT Agreement without the written consent of SIIL; (iv) not amend or modify the MIT Agreement in a manner that will adversely affect SIIL’s rights under this Agreement or the MIT Agreement, without SIIL’s prior written consent;
(v) not exercise any right to itself terminate or waive any material right under the MIT Agreement, which waiver would adversely affect SIIL’s rights under this Agreement or the MIT Agreement without the prior written consent of SIIL; and
(vi) to the extent practicable, notify SIIL prior to any termination of the MIT Agreement. In addition, Visterra shall promptly provide SIIL with a copy of any amendments to the MIT Agreement made after the Effective Date. 

10.5. Disclaimer. SIIL understands that the Product is the subject of ongoing clinical research and development and that Visterra
cannot assure the safety or efficacy of the Product. 
 10.6. No Other Representations or Warranties. EXCEPT AS EXPRESSLY
STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY,  

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 34

 
FITNESS FOR A PARTICULAR PURPOSE, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES OTHER THAN THOSE EXPRESSLY STATED IN THIS AGREEMENT, WHETHER ARISING BY OPERATION
OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 
 10.7. Export Control. Visterra and its Affiliates shall comply with all United
States laws and regulations controlling the export of certain commodities and technical data, including all Export Administration Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit or
require a license for the export of certain types of commodities and technical data to specified countries. Visterra hereby gives written assurance that it shall comply with, and shall cause its Affiliates to comply with, all United States export
control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates, and that it shall indemnify, defend, and hold SIIL harmless (in accordance with Section 11.2) for the
consequences of any such violation. SIIL hereby gives written assurance that it shall comply with, and shall cause its Affiliates to comply with, all applicable import control laws and regulations, that it bears sole responsibility for any violation
of such laws and regulations by itself or its Affiliates, and that it shall indemnify, defend, and hold Visterra harmless (in accordance with Section 11.2) for the consequences of any such violation. Each Party shall reasonably cooperate with the
other Party in facilitating such Party’s or its Affiliates’ compliance with any such laws and regulations. 
 ARTICLE 11

 INDEMNIFICATION 

11.1. Indemnification by Visterra. Visterra hereby agrees to defend, hold harmless and indemnify (collectively
“Indemnify”) SIIL and its Affiliates, agents, directors, officers and employees (the “SIIL Indemnitees”) from and against any and all liabilities, expenses or losses, including without limitation reasonable legal
expenses and attorneys’ fees (collectively “Losses”) in each case resulting from Third Party suits, claims, actions and demands (each, a “Third Party Claim”) arising directly or indirectly out of (a) a
breach of any of Visterra’s obligations under this Agreement, including without limitation Visterra’s representations and warranties or covenants set forth in Article 10, (b) the negligence or willful misconduct of any Visterra
Indemnitee, or (c) the research, Development, Manufacture or Commercialization of Licensed Antibodies and/or Products by, or on behalf of, the Visterra Indemnitees in the Visterra Territory. Visterra’s obligation to Indemnify the SIIL
Indemnitees pursuant to this Section 11.1 shall not apply to the extent that any such Losses are subject to indemnification by SIIL pursuant to Section 11.2. 

11.2. Indemnification by SIIL. SIIL hereby agrees to Indemnify Visterra and its Affiliates, licensees, agents, directors, officers and
employees (the “Visterra Indemnitees”) from and against any and all Losses resulting from Third Party Claims arising directly or indirectly out of (a) a breach of any obligations of SIIL under this Agreement, including without
limitation SIIL’s representations and warranties or covenants set forth in Article 10; (b) the research, Development, Manufacture or Commercialization of Products by SIIL or its Affiliates in the Licensed Territory; or (c) the
negligence or willful misconduct of any SIIL Indemnitee. SIIL’s obligation to Indemnify the Visterra Indemnitees pursuant to the foregoing sentence shall 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 35

 
not apply to the extent that any such Losses are subject to indemnification by Visterra pursuant to Section 11.1. 

11.3. Procedure. The indemnified Party shall provide the indemnifying Party with prompt notice of the claim giving rise to the
indemnification obligation pursuant to this Article 11 and the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or settle any such claim; provided, however, that the indemnifying Party shall not
enter into any settlement for damages other than monetary damages without the indemnified Party’s written consent, such consent not to be unreasonably withheld. The indemnified Party shall have the right to participate, at its own expense and
with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party. If the Parties cannot agree as to the application of Sections 11.1 and 11.2 to any particular Third Party Claim, the Parties may conduct
separate defenses of such Third Party Claim. Each Party reserves the right to claim indemnity from the other in accordance with Sections 11.1 and 11.2, as applicable, upon resolution of the underlying claim, notwithstanding the provisions of this
Section 11.3 requiring the indemnified Party to tender to the indemnifying Party the exclusive ability to defend such claim or suit. 

11.4. Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, INDIRECT, OR
CONSEQUENTIAL DAMAGES OR LOSS OF PROFITS OR OPPORTUNITY OR DIMINUTION OF GOODWILL ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS
INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 OR 11.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 12. 

11.5. Insurance. Each Party shall procure and maintain insurance, including product liability insurance, at all times during which any
Product is being clinically tested in human subjects or commercially distributed or sold by such Party in coverages and amounts appropriate in light of the commercially available coverage and the obligations of such Party hereunder, and which are
consistent with normal business practices of prudent companies similarly situated. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under
this Article 11. Each Party shall provide the other Party with written evidence of such insurance upon request, if insurance company so agrees. Each Party shall provide the other Party with written notice at least thirty (30) days prior to the
cancellation, non-renewal or material change in such insurance which materially adversely affects the rights of the other Party hereunder. 

ARTICLE 12 

CONFIDENTIALITY 
 12.1.
Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 36

 
shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any
obligations hereunder) any Confidential Information of the other Party pursuant to this Agreement. The foregoing confidentiality and non-use obligations shall not apply to any portion of the Confidential Information that the receiving Party can
demonstrate by competent written proof: 
 (a) was already known to the receiving Party or its Affiliate, other than under an
obligation of confidentiality, at the time of disclosure by the other Party; 
 (b) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally available to
the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 

(d) is subsequently disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such disclosure;
or 
 (e) is subsequently independently discovered or developed by the receiving Party or its Affiliate without the aid,
application, or use of the disclosing Party’s Confidential Information, as evidenced by a contemporaneous writing. 
 12.2.
Authorized Disclosure. Notwithstanding the obligations set forth in Section 12.1, a Party may disclose the other Party’s Confidential Information and the terms of this Agreement to the extent: 

(a) such disclosure: (i) is reasonably necessary for the filing or prosecuting patent rights as contemplated by this Agreement; or
(ii) is reasonably necessary for the prosecuting or defending litigation as contemplated by this Agreement; 
 (b) such
disclosure is reasonably necessary: (i) to such Party’s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to
provide advice to the receiving Party; provided that in each such case on the condition that such directors, attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations consistent with those
contained in this Agreement; or (ii) to actual or potential investors or acquirers solely for the purpose of evaluating an actual or potential investment or acquisition; provided that in each such case on the condition that such actual
or potential investors or acquirers are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; 

(c) such disclosure is required by judicial or administrative process; provided that in such event such Party shall promptly
inform the other Party such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise
subject to the confidentiality and non-use provisions of this Article 12, and the Party 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 37

 
disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order to ensure the
continued confidential treatment of such Confidential Information; 
 (d) such disclosure is reasonably necessary to its
collaborators in its respective territory (including contract research organizations, hospitals, doctors, consultants, subcontractors and Affiliates) for the purpose of the Development, Manufacture or Commercialization of the Products, solely for
the purpose of carrying out such collaboration, on the condition that such collaborators are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; 

(e) such disclosure is reasonably necessary to its potential collaborators to have such potential collaborators to evaluate the
possibility of entering into an agreement with the disclosing Party on condition that such potential collaborators are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; or 

(f) in the case of disclosure of SIIL’s Confidential Information by Visterra, such disclosure is made to MIT as required by the
terms of the MIT Agreement. 
 12.3. Publication. 

(a) Visterra shall develop and present to the JSC for its review and comment a global branding strategy for Products in the Field
throughout the world, including a life cycle plan, brand vision, positioning, key messaging, concept and imagery, brand public relations and supporting market research (a “Publication Strategy”). 

(b) SIIL shall deliver to Visterra a copy of any proposed publication or presentation relating to the Product for Visterra’s
review and approval. Visterra shall have the right to require modifications of the proposed publication or presentation for reasons such as: (a) to protect Visterra’s Confidential Information; (b) for trade secret reasons or business
reasons; or (c) to delay such submission for an additional ninety (90) days as may be reasonably necessary to seek patent protection for any Sole Inventions owned by Visterra or any Joint Invention disclosed in such proposed submission.
Any publication or presentation by SIIL relating to the Product shall be consistent with the Publication Strategy. Visterra shall be free to publish/present with respect to the Product in its discretion and without review or approval of SIIL,
provided that such publication/presentation does not include Confidential Information of SIIL without SIIL’s written consent (not to be unreasonably withheld). 

12.4. Publicity; Use of Names. Subject to Section 12.2 and the rest of this Section 12.4, no disclosure of the terms of this Agreement
may be made by either Party or its Affiliates, and no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or other public disclosure
relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by law. 

(a) A Party may disclose this Agreement and its terms in filings with the Securities Exchange Commission (or equivalent foreign agency)
(“SEC”), tax authorities, bankers (in connection with payments from SIIL), governmental authorities or other regulatory 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 38

 
agencies to the extent required by law after complying with the procedures set forth in this Section 12.4. In such event, the Party seeking such disclosure shall prepare a draft confidential
treatment request and a proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than [**] Business Days after receipt of such confidential
treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the time lines proscribed by applicable regulations. The Party seeking such disclosure shall
exercise Commercially Reasonable Efforts to obtain confidential treatment of this Agreement from the SEC or other regulatory agency as represented by the redacted version reviewed by the other Party. 

(b) Further, each Party acknowledges that the other Party may be legally required to make public disclosures (including in filings with
the SEC or other agency) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by law; provided that, where possible, the Party seeking such
disclosure first provides the other Party a copy of the proposed disclosure; and provided further that (except to the extent that the Party seeking disclosure is required to disclose such information to comply with applicable Laws) if the
other Party demonstrates to the reasonable satisfaction of the Party seeking disclosure, within [**] Business Days of such Party’s providing the copy, that the public disclosure of previously undisclosed information shall materially adversely
affect the Development or Commercialization of a Product being developed or commercialized, the Party seeking disclosure shall remove from the disclosure such specific previously undisclosed information as the other Party shall reasonably request to
be removed. 
 (c) Notwithstanding the foregoing, the Parties will agree on language of a press release announcing the collaboration
no later than thirty (30) days after the execution of this Agreement by both Parties and shall issue such press release promptly thereafter. 

(d) The Parties agree that after a disclosure pursuant to Sections 12.4(a) or 12.4(b) has been reviewed and approved by the other
Party, the disclosing Party may make subsequent public disclosures or issue a press release disclosing the same content without having to obtain the other Party’s prior consent and approval. 

12.5. Non-Use of MIT Names. SIIL and its Affiliates shall not use the name of “Massachusetts Institute of Technology,”
“Lincoln Laboratory” or any variation, adaptation, or abbreviation thereof, or of any of its trustees, officers, faculty, students, employees, or agents, or any trademark owned by MIT, or any terms of the MIT Agreement in any promotional
material or other public announcement or disclosure. 
 12.6. Equitable Relief. Each Party and its Affiliates acknowledge that
a breach of this Article 12 cannot reasonably or adequately be compensated in damages in an action at law and that such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each Party and its Affiliates agree that
the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to
Confidential Information set forth herein by the other Party. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 39

 12.7. Obligation Period. The obligations of the Parties under this Article 12 shall
continue for a period of [**] years after the expiration of, or [**] years after the earlier termination of, this Agreement. 

ARTICLE 13 
 TERM AND
TERMINATION 
 13.1. Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to
this Article 13 or Section 15.5, shall remain in effect, on a country-by-country basis, until the expiration of the Royalty Term of the Product in such country (“Term”). Upon the expiration of the Term in a particular country,
the license granted to SIIL under the Visterra Technology in such country shall become perpetual, fully-paid and royalty-free; provided that any license to the Visterra Technology that is in-licensed under the MIT Agreement shall be
non-exclusive upon such expiration. 
 13.2. Termination for Breach. 

(a) Notice. If either Party believes that the other Party is in material breach of this Agreement, then the Party holding such belief
(the “Non-Breaching Party”) may deliver notice of such breach to the other Party (the “Notified Party”). The Notified Party shall have [**] days to cure such breach to the extent involving non-payment of undisputed
amounts due and payable hereunder, and [**] days to either cure such breach for all other material breaches. If the Notified Party fails to cure a material breach of this Agreement as provided for in this Section 13.2(a), then the Non-Breaching
Party may terminate this Agreement upon written notice to the Notified Party. Notwithstanding the foregoing, if cure of a breach other than non-payment cannot reasonably be effected within such [**] day period, the Notified Party may deliver to the
Non-breaching Party a plan reasonably calculated to cure such breach within a timeframe that is reasonably prompt in light of the circumstances then prevailing but in no event longer than an additional [**] days. Following delivery of such a plan,
the Notified Party shall carry out the plan and cure the breach within the timeframe set forth in the plan and the failure of the Notified Party to cure the breach within such timeframe shall result in the immediate and automatic termination of this
Agreement upon the expiration of such timeframe. Without limiting the foregoing, if SIIL materially breaches this Agreement with respect to the Manufacture of the Product and fails to timely cure such breach as provided in this Section 13.2(a),
Visterra may elect to terminate this Agreement solely with respect to the rights granted to SIIL hereunder to make, have made or otherwise Manufacture the Licensed Antibody and Product upon written notice to SIIL. If Visterra so elects, promptly
following the effective date of such termination, the Parties will negotiate and agree upon an agreement pursuant to which Visterra would Manufacture and supply Licensed Antibody and Product to SIIL for Development and Commercialization in the
Licensed Territory. 
 (b) Disputes. If a Party gives notice of termination under this Section 13.2 and the other Party
disputes whether such termination is proper under this Section 13.2, then the issue of whether this Agreement may properly be terminated upon expiration of the notice period (unless such breach is cured as provided in Section 13.2(a)) shall be
resolved in accordance with Article 14. If as a result of such dispute resolution process it is determined that the notice of 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 40

 
termination was proper, then such termination shall be deemed to be effective on the date of termination based on the original termination notice prior to the initiation of the related dispute
or, if later, [**] days following the resolution of the relevant dispute. If as a result of such dispute resolution process it is determined that the notice of termination was improper, then no termination shall have occurred and this Agreement
shall remain in effect. 
 (c) Royalty Reduction. If Visterra materially breaches this Agreement and such breach is not cured within
the applicable notice period set forth in Section 13.2(a), SIIL, at its sole discretion, may either: 
 (i) terminate this
Agreement in accordance with Section 13.2 (in addition to pursuing any remedy that may be available to SIIL at law or in equity as a result of Visterra’s breach of this Agreement); or 

(ii) elect (A) not to terminate this Agreement, (B) to retain the license granted under Section 2.1, subject to all terms
and conditions hereof, and (C) pursue any remedy that may be available to SIIL at law or in equity as a result of Visterra’s breach of this Agreement, without prejudice to SIIL’s right to terminate this Agreement at a later date
pursuant to Section 13.2 (for that uncured material breach or any other uncured material breach of this Agreement by Visterra). If SIIL so elects not to terminate this Agreement and such breach is undisputed or it is finally determined pursuant to
Section 13.2(b) that such notice was proper, thereafter (x) the JSC shall be disbanded and, in lieu thereof, within [**] days after the end of each Calendar Year, SIIL shall deliver a written report to Visterra summarizing in reasonable detail
SIIL’s efforts to Develop the Product during the just-ended Calendar Year and (y) the royalty rates set forth in Section 8.3(a) shall be reduced by [**] percent ([**]%) with respect to Net Sales occurring after the date of such notice.

 13.3. Termination by SIIL. SIIL may terminate this Agreement without cause on (a) ninety (90) day’s prior
written notice if the First Commercial Sale of the Product in the Licensed Territory has not occurred or (b) one hundred eighty (180) day’s prior written notice if the First Commercial Sale of the Product in the Licensed Territory has
occurred. 
 13.4. Termination for Patent Challenge. If SIIL or any of its Affiliates (a) commences or participates in
any action (including any patent opposition, re-examination or invalidation proceeding), or otherwise asserts any claim, challenging or denying the validity or enforceability of any Visterra Patents or any claim thereof or (b) actively assists
any person or entity in bringing or prosecuting any action (including any patent opposition, re-examination or invalidation proceeding) challenging or denying the validity or enforceability of any Visterra Patents or any claim thereof (each of
(a) and (b), a “Patent Challenge”), then, to the extent permitted by Law, Visterra may, in its sole discretion, give at least thirty (30) days prior written notice to SIIL that Visterra may terminate this Agreement, and,
unless SIIL or its Affiliates, as applicable, withdraw or cause to be withdrawn all such challenges within thirty (30) days after SIIL’s receipt of notice regarding such Patent Challenge, Visterra may terminate this Agreement by providing
written notice thereof to SIIL. 
 13.5. Visterra Rights upon Termination of this Agreement. If this Agreement is terminated
(but not if this Agreement expires in accordance with its terms) upon such early 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 41

 
termination of this Agreement, the following shall apply (in addition to any other rights and obligations otherwise under this Agreement with respect to such termination): 

(a) Regulatory Filings; Data. To the extent permitted by applicable Laws, SIIL shall transfer and assign to Visterra all Regulatory
Filings, Regulatory Approvals, and related preclinical, analytical, and clinical data for the Product throughout the Licensed Territory. If the transfer of any such Regulatory Filings, Regulatory Approvals, and related preclinical, analytical, and
clinical data is prohibited by applicable Laws, SIIL shall grant Visterra an exclusive, perpetual, royalty-free, license and a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) and any foreign counterpart to such
regulation, to such Regulatory Filings, Regulatory Approvals, and related preclinical, analytical, and clinical data to Develop, Manufacture or Commercialize the Licensed Antibody or Product and shall cooperate in good faith with Visterra to allow
Visterra to make full use thereof, including by executing documents and making filings with Regulatory Authorities upon Visterra’s reasonable request. 

(b) SIIL License. Within sixty (60) days following the effective date of termination, Visterra may elect upon written notice to
SIIL to receive the license provided for in this Section 13.5(b). Effective upon SIIL’s receipt of Visterra’s election to receive such license, SIIL hereby grants to Visterra, a non-exclusive, royalty-bearing license under SIIL Technology
to Develop, make, have made, use, sell, offer for sale, have sold, import and otherwise Commercialize Products in the Licensed Territory, which license shall be effective as of the date of such termination. In consideration for such license, the
Parties shall agree to, and Visterra shall pay SIIL, a commercially reasonable royalty on Net Sales of Products in the Licensed Territory which royalty shall be determined by the Parties taking into account the commercial value of such SIIL
Technology and the value of any Product Marks assigned to Visterra pursuant to Section 13.5(b); provided, that in no event shall the royalty payable by Visterra to SIIL under this Section 13.5(b) exceed the royalty rate payable by SIIL under Section
8.3. 
 (c) Transition Assistance. SIIL shall provide such reasonable assistance, at no cost to Visterra (except as set forth
in Section 13.6), as may be reasonably necessary or useful for Visterra to commence or continue, at Visterra’s cost, Developing or Commercializing Products in the Licensed Territory, to the extent SIIL is then performing or having performed
such activities, including without limitation transferring or amending as appropriate, upon request of Visterra, any agreements or arrangements with Third Party vendors to sell Products in the Licensed Territory. To the extent that any such contract
between SIIL and a Third Party is not assignable to Visterra, then SIIL shall reasonably cooperate with Visterra to arrange to continue to provide and provide such services from such entity. 

(d) If this Agreement is terminated by Visterra under Section 13.2(a) solely with respect to the Manufacture of the Licensed Antibody
or Product by SIIL, the provisions of this Section 13.5 shall apply solely with respect to such terminated rights and all other rights and obligations of SIIL hereunder shall survive. 

13.6. Payment by Visterra. If this Agreement is terminated for any reason, Visterra shall reimburse SIIL for all reasonable and
documented out-of-pocket and internal costs (including labor costs) incurred by SIIL in performing its obligations in Sections 13.5(a) through 13.5(c); provided, that if this Agreement is terminated by Visterra pursuant to Section 13.2 or

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 42

 
13.4, Visterra may seek to recover such amounts as part of any dispute resolution proceeding brought by Visterra with respect to the breach or Patent Challenge giving rise to such termination.

 13.7. Survival. Any expiration or termination of this Agreement will be without prejudice to the rights of either Party against
the other accrued or accruing under this Agreement prior to expiration or termination, including payment obligations arising prior to, or as a result of a Party’s exercise of its rights or performance under this Agreement prior to, such
expiration or termination. The following provisions shall survive any expiration or termination of this Agreement: Articles 1, 11 (provided that Section 11.5 shall survive solely to the extent applicable to a Party’s obligations following
expiration or termination of the Agreement), 12 and 14 and Sections 2.2(b), 2.2(c), 2.2(d), 2.3(d), 4.5, 4.6, Sentences 3, 6 and 7 of Section 5.5, 6.4, 8.3(e), 8.4, 8.5, 8.6, 8.7, 9.1, 9.2, 10.6, 10.7, 13.1, 13.5, 13.6, 13.7, 15.1, 15.3, 15.4
and 15.6 through 15.13. 
 ARTICLE 14 

DISPUTE RESOLUTION 

14.1. Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the Term which relate to
either Party’s rights or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner. 

14.2. Internal Resolution. With respect to all disputes arising between the Parties under this Agreement, including any alleged breach
under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute within thirty (30) days after such dispute is first identified by either Party in writing to
the other, the Parties shall refer such dispute to the Chief Executive Officers of the Parties (or any senior executive reporting directly to either Party’s Chief Executive Officer) for attempted resolution by good faith negotiations within
thirty (30) days after such notice is received. If no resolution is reached, then each Party may seek any legal remedy available to it to the extent permitted under this Agreement. 

ARTICLE 15 

MISCELLANEOUS 
 15.1.
Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between
the Parties with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 43

 
subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized representative of each Party. 

15.2. Force Majeure. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such
performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming
Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the reasonable control of the nonperforming Party, including without limitation, an act of God or terrorism,
involuntary compliance with any regulation, law or order of any government, war, civil commotion, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or
like catastrophe. Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. If a force majeure persists for more than ninety (90) days, then the Parties
shall discuss in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate the delays caused by such force majeure. 

15.3. Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this
Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.3, and shall be deemed to have been given for all
purposes (a) when received, if hand-delivered or sent by confirmed facsimile or a reputable courier service, or (b) five (5) Business Days after mailing, if mailed by first class certified or registered airmail, postage prepaid,
return receipt requested. 
  

			
	If to Visterra:	 	Visterra, Inc.
		 	One Kendall Square, Suite B3301
		 	Cambridge, MA 02139
		 	Attention: Chief Executive Officer
		 	Fax: 617 498-1073
		
	With a copy to:	 	Visterra, Inc.
		 	One Kendall Square, Suite B3301
		 	Cambridge, MA 02139
		 	Attention: Legal Department
		 	Fax: 617 498-1073
		
	And a copy to:	 	Cooley LLP
		 	One Freedom Square
		 	Reston Town Center
		 	11951 Freedom Drive
		 	Reston, VA 20190-5656
		 	Attn: Kenneth J. Krisko
		 	Fax: 703-456-8100

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 44

			
	If to SIIL:	 	Serum Institute of India Ltd.
		 	401, Sarosh Bhavan
		 	16-B/1 Dr. Ambedkar Road
		 	Pune 411001, INDIA
		 	Attention: Makarand Karkare, Company Secretary
		 	Fax: +91 20 26133228

 15.4. No Strict Construction; Headings. This Agreement has been prepared jointly and shall not be
strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in
this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

15.5. Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written
consent of the other, except that a Party may make such an assignment without the other Party’s consent to Affiliates or to a successor to substantially all of the business of such Party to which this Agreement relates (whether by merger, sale
of stock, sale of assets or other change of control transaction) (an “Acquisition”). Notwithstanding the foregoing, a stock sale to the underwriters of a public offering of a Party’s capital stock or to other Third Parties
solely for the purpose of financing or a transaction solely to change the domicile of a Party shall not constitute an Acquisition. Any permitted successor or assignee of rights or obligations hereunder shall, in writing to the other Party, expressly
assume performance of such rights or obligations. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 15.5 shall be
null, void and of no legal effect. In the event of an Acquisition of a Party (the “Acquisition Party”), the Acquisition Party shall, as soon as reasonably practicable following first public announcement of such Acquisition, provide
the other Party with written notice of such Acquisition, after which, the other Party shall, for a period of [**] calendar days from such Party’s receipt of notice from the Acquisition Party, have the absolute right and discretion to terminate
this Agreement by providing the Acquisition Party with a written notice of termination within such [**] calendar day period, which termination shall be effective [**] days from the Acquisition Party’s receipt of such notice of termination.

 15.6. Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its
Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any
breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such
Party’s Affiliate. 
 15.7. Severability. If any one or more of the provisions of this Agreement is held to be invalid or
unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 45

 
invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives
contemplated by the Parties when entering this Agreement may be realized. 
 15.8. No Waiver. Any delay in enforcing a Party’s
rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written
and signed waiver relating to a particular matter for a particular period of time. 
 15.9. Independent Contractors. Each
Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the
relationship of partners, principal and agent, or joint-venture partners between the Parties. 
 15.10. English Language. This
Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. To the extent this Agreement requires a Party to provide to the other Party Information,
correspondence, notice or other documentation, such Party shall provide such Information, correspondence, notice or other documentation in the English language. 

15.11. Governing Law. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be
governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state. 

15.12. Counterparts. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. In addition, this Agreement may be executed by facsimile or “PDF” and such facsimile or “PDF” signature shall be deemed to be an original. 

15.13. Certain Conventions. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit
shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires,
(a) all definitions set forth herein shall be deemed applicable whether the words defined are used herein with initial capital letters in the singular or the plural, (b) the word “will” shall be construed to have the same meaning
and effect as the word “shall,” (c) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (d) any reference herein to any entity shall be construed to include the entity’s successors and assigns,
(e) the word “notice” shall mean notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (f) provisions that
require that a Party, the Parties or any committee hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 46

 
agreement, letter, approved minutes or otherwise, (g) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the
then-current amendments thereto or any replacement or successor law, rule or regulation thereof and (h) the term “or” shall be interpreted in the inclusive sense commonly associated with the term “and/or”, (i) words of
any gender include each other gender, (j) words such as “herein”, “hereof” and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (k) words
using the singular shall include the plural, and vice versa, (l) the words “include,” “includes” and “including” shall be deemed to be followed by the phrase “but not limited to”, “without
limitation”, “inter alia” or words of similar import and (m) unless “Business Days” is specified, “days” shall mean “calendar days.” 

[Signature Page Follows] 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 47

 IN WITNESS WHEREOF, the Parties have executed
this Agreement in duplicate originals by their duly authorized representatives as of the Effective Date. 
  

									
	VISTERRA, INC.	 		 	SERUM INSTITUTE OF INDIA LTD.
					
	By:	 	  /s/ Brian J. G. Pereira
	 		 	By:	 	  /s/ Adar C. Poonawalla

					
	Name:	 	Brian J. G. Pereira	 		 	Name:	 	Adar C. Poonawalla
					
	Title:	 	CEO	 		 	Title:	 	CEO and Executive Director

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Page 48

 Exhibit A 

Licensed Antibody 
 VH amino acid
sequence 
 [**] 
 VL amino acid sequence

 [**] 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Exhibit A

 Exhibit B 

Visterra Patents 
  

																											
	 Client

Matter
	  	 Type
	  	 Status
	 	  	 App. No.
	 	  	 File Date
	 	  	 Country
	 	  	 Client Ref.
	 	  	 Title
	 
	 [**]
	  	[**]	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  
	 [**]
	  	[**]	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Exhibit B

 Exhibit C 

Research and Development Plan 

Research and Development Plan for 

Dengue Monoclonal Antibody (VIS513) 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of five pages were omitted. [**] 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Exhibit C

 Schedule 2.8 

Technology Transfer 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of one page was omitted. [**]. 

  

					
	License Agreement SIIL-Visterra – EXECUTION VERSION	 	Schedule 2.8EX-10.16

 Exhibit 10.16 

INDEMNIFICATION AGREEMENT 

THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of
[            ], by and between VISTERRA, INC., a Delaware corporation (the “Company”), and
[            ] (the “Indemnitee”). 

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to
serve as officers of the Company and directors on the Company’s Board of Directors and to indemnify its officers and directors so as to provide them with the maximum protection permitted by law. 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain
qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance
has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at
higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among
other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Certificate of Incorporation of the Company requires indemnification of the officers and directors of the Company.
Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (“DGCL”). The Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set
forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification; 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining
such persons; 
 WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is
detrimental to the best interests of the Company’s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses
on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; 

WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation of the Company and any resolutions
adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and 

  
 1 

 WHEREAS, Indemnitee does not regard the protection available under the Company’s
Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as a[n] [officer] [and] [or] [director] without adequate protection, and the Company desires Indemnitee to serve in such capacity.
Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified[.] [; and] 

1[WHEREAS, Indemnitee is a representative of [•] [and its affiliated
investment funds] (the “Fund”), and has certain rights to indemnification and/or insurance provided by the Fund which Indemnitee and the Fund intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as
provided herein, with the Company’s acknowledgement and agreement to the foregoing being a material condition to Indemnitee’s willingness to serve as a member of the Company’s Board. 

NOW, THEREFORE, in consideration of Indemnitee’s agreement to serve as a[n] [officer] [and] [or]
[director] of the Company and other good and valuable consideration, Company and Indemnitee hereby agree as follows: 
 1.
Indemnification; Presumptions.  
 (a) Indemnification. The Company shall indemnify, defend, and hold harmless
Indemnitee from and against, and shall compensate and reimburse Indemnitee for, any Damages (as defined below) that are directly or indirectly suffered or incurred by Indemnitee as a result of, or are directly or indirectly connected with, any
threatened, pending or completed action or proceeding, whether civil, criminal, administrative or investigative, to which Indemnitee is or was a party, or is threatened to be made a party, by reason of, or arising directly or indirectly from, the
fact that Indemnitee is or was an officer or a member of the Company’s Board or the board of directors of any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee in his or her role as an officer or a member
of the Company’s Board or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of the Company or of another corporation, partnership, joint venture, trust or other
enterprise (“Corporate Status”), provided however, that the Company shall not be obligated to indemnify Indemnitee under this Section 1: (1) if the Company (including its Board of Directors, any committee or subgroup of
the Board of Directors, independent legal counsel, or its shareholders) can demonstrate that Indemnitee acted in bad faith and in a manner Indemnitee could not reasonably have believed to be in or not opposed to the best interests of the Company,
and, with respect to any criminal action or proceeding, that Indemnitee had no reasonable cause to believe Indemnitee’s conduct was lawful; or (2) in an action by or in the right of the Company, for any claim, issue or matter as to which
Indemnitee shall have been adjudged to be liable to the Company in the performance of any duty to the Company and its shareholders unless and only to the extent that the 

 

	1 	 Include this recital and the other bracketed provisions where indicated throughout if the Indemnitee is affiliated with a venture capital fund or
other entity that provides indemnification to the Indemnitee. 

  
 -2- 

 
court in which such action or proceeding is or was pending shall determine upon application that, in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to
indemnity for expenses and then only to the extent that the court shall determine. “Damages” shall include any loss, damage, injury, liability, claim, demand, settlement, judgement, award, fine, penalty, tax, fee (including any legal fee,
expert fee, accounting fee or advisory fee), charge, cost (including any cost of investigation) or expense of any nature and to the fullest extent permitted by applicable law. 

(b) Presumptions. 
 (i) In
making a determination with respect to entitlement to indemnification hereunder, the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its shareholders) shall presume that
Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. Indemnitee shall be deemed to have acted in
good faith if Indemnitee’s action is based on the records or books of account of the Company, including financial statements, or on information supplied to Indemnitee by the officers of the Company in the course of their duties, or on the
advice of legal counsel for the Company or on information or records given or reports made to the Company by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Company. The termination
of any action or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that (i) Indemnitee did not act in good faith, (ii) Indemnitee did not
act in a manner which Indemnitee reasonably believed to be in the best interests of the Company, or (iii) with respect to any criminal action or proceeding, Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful.
In addition, it shall be presumed that Indemnitee has at all times acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have
the burden of proof and the burden of persuasion by clear and convincing evidence. 
 (ii) The Company acknowledges that a settlement or
other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any
manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful
on the merits or otherwise in such action, suit or proceeding. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. 

(iii) The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or
employee of the Company shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. 

  
 -3- 

 2. Expenses; Indemnification Procedure. 

(a) Advancement of Expenses. The Company shall advance all expenses incurred by Indemnitee in connection with the investigation,
defense, settlement or appeal of any civil or criminal action or proceeding referenced in Section 1 hereof (but not amounts actually paid in settlement of any such action or proceeding). Indemnitee hereby undertakes to repay such amounts
advanced only if, and to the extent that, it shall ultimately be determined by a court of competent jurisdiction that such expenses were not reasonable or that Indemnitee is not entitled to be indemnified by the Company as authorized hereby. The
advances to be made hereunder shall be paid by the Company to Indemnitee within twenty (20) days following delivery of a written request therefor by Indemnitee to the Company. 

(b) Notice/Cooperation by Indemnitee. Indemnitee shall, as a condition precedent to his or her right to be indemnified under this
Agreement, give the Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the Secretary of the Company
at the address shown on the signature page of this Agreement (or such other address as the Company shall designate in writing to Indemnitee). In addition, Indemnitee shall give the Company such information and cooperation as it may reasonably
require and as shall be within Indemnitee’s power. Notwithstanding the foregoing, any failure of Indemnitee to provide such notice to the Company, or to provide such notice in a timely fashion, shall not relieve the Company of any liability
that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company. 

(c) Procedure. Any indemnification provided for in Section 1 shall be made no later than forty-five (45) days after receipt of
the written request of Indemnitee. If a claim under this Agreement, under any statute, or under any provision of the Company’s Certificate of Incorporation or By-laws providing for indemnification, is not paid in full by the Company within
forty-five (45) days after a written request for payment thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and,
subject to Section 16 of this Agreement, Indemnitee shall also be entitled to be paid for the expenses (including attorneys’ fees) of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a
claim for expenses incurred in connection with any action or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify Indemnitee
for the amount claimed, but the burden of proving such defense shall be on the Company and shall be in accordance with Subsection 1(b), and Indemnitee shall be entitled to receive interim payments of expenses pursuant to Subsection 2(a) unless and
until such defense may be finally adjudicated by court order or judgment from which no further right of appeal exists. It is the parties’ intention that if the Company contests Indemnitee’s right to indemnification, the question of
Indemnitee’s right to indemnification shall be for the court to decide, and neither the failure of the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its
shareholders) to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the

  
 -4- 

 
Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its shareholders) that Indemnitee has not met such applicable
standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. 
 (d) Selection of
Counsel. In the event the Company shall be obligated under Section 2(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel
approved by Indemnitee, which approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of its election so to do. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such
counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that (i) Indemnitee shall have the right
to employ his or her counsel in any such proceeding at Indemnitee’s expense; and (ii) if (A) the employment of counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded
that there may be a conflict of interest on any significant issue between the Company and Indemnitee in the conduct of any such defense or (C) the Company shall not, in fact, have employed counsel to assume the defense of such proceeding, then
the fees and expenses of Indemnitee’s counsel shall be at the expense of the Company. 
 3. Additional Indemnification Rights;
Nonexclusivity; Subrogation[; Primacy of Indemnification2]. 
 (a) Scope.
Notwithstanding any other provisions of this Agreement, the Company hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of
this Agreement, the Company’s Certificate of Incorporation, the Company’s By-laws or by statute. In the event of any change, after the date of this Agreement, in any applicable law, statute or rule which expands the right of a Delaware
corporation to indemnify a member of its Board, such changes shall be, ipso facto, within the purview of Indemnitee’s rights and Company’s obligations, under this Agreement. In the event of any change in any applicable law, statute
or rule which narrows the right of a Delaware corporation to indemnify a member of its Board, such changes, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or
the parties’ rights and obligations hereunder. 
 (b) Nonexclusivity. The indemnification provided by this Agreement shall not be
deemed exclusive of any rights to which Indemnitee may be entitled under the Company’s Certificate of Incorporation, its By-laws, any agreement, any vote of shareholders or disinterested directors, Delaware law, or otherwise, both as to action
in Indemnitee’s official capacity and as to action in another capacity while holding such office. The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while serving in an 

 

	2 	 Include this provision if the Indemnitee is affiliated with a venture capital fund or other entity that provides indemnification to the Indemnitee.

  
 -5- 

 
indemnified capacity even though he or she may have ceased to serve in such capacity at the time of any action or otherwise covered proceeding. To the extent that the Company maintains an
insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the
coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in
effect, the Company shall give prompt notice of such claim or of the commencement of an indemnifiable action or proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such action or proceeding in accordance with the terms of such policies. 

(c) Subrogation. In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all
of the rights of recovery of Indemnitee [(other than any rights of recovery of Indemnitee from a Fund Indemnitor (as defined in Section 3(d) hereof) or under any insurance provided by the Fund or its affiliates)]3, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such
rights. 
 [(d) Primacy of Indemnification. The Company hereby acknowledges that Indemnitee has certain rights to indemnification,
advancement of expenses and/or insurance provided by the Fund and certain of its affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to
Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full
amount of expenses incurred by Indemnitee and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the Certificate of Incorporation or
By-laws (or any agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all
claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any
claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of
recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms hereof.]4 

 

	3 	Include this provision if the Indemnitee is affiliated with a venture capital fund or other entity that provides indemnification to the Indemnitee. 

	4 	Include this provision if the Indemnitee is affiliated with a venture capital fund or other entity that provides indemnification to the Indemnitee. 

  
 -6- 

 4. Partial Indemnification. If Indemnitee is entitled under any provision of this
Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred by Indemnitee in the investigation, defense, appeal or settlement of any civil or criminal action or
proceeding, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled. 

5. Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that
Indemnitee is, by reason of his or her Corporate Status, a witness, or is made (or asked) to respond to discovery requests, in any action or proceeding to which Indemnitee is not a party, he or she shall be indemnified against all expenses actually
and reasonably incurred by him or her or on his or her behalf in connection therewith. 
 6. Mutual Acknowledgment. Both
the Company and Indemnitee acknowledge that in certain instances, Federal law or applicable public policy may prohibit the Company from indemnifying its directors, officers or other advisors under this Agreement or otherwise. Indemnitee understands
and acknowledges that the Company has undertaken or may be required in the future to undertake with the Securities and Exchange Commission to submit the question of indemnification to a court in certain circumstances for a determination of the
Company’s right under public policy to indemnify Indemnitee. 
 7. Severability. Nothing in this Agreement is
intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order, to perform its obligations under this Agreement shall not
constitute a breach of this Agreement. The provisions of this Agreement shall be severable as provided in this Section 7. If this Agreement or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then
the Company shall nevertheless indemnify Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not have invalidated, and the balance of this Agreement not so invalidated shall be enforceable in accordance
with its terms. 
 8. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for
in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for expenses, judgments, fines or penalties actually or
reasonably incurred in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such indemnifiable event in order to reflect
(i) the relative benefits received by the Company, on the one hand, and Indemnitee, on the other hand, as a result of the event(s) and/or transaction(s) giving cause to the indemnifiable event; and/or (ii) the relative fault of the Company
(and its other directors, officers, employees and agents), on the one hand, and Indemnitee, on the other hand, in connection with such event(s) and/or transaction(s). 

  
 -7- 

 9. Exceptions. Any other provision herein to the contrary notwithstanding, the
Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee or to advance expenses in connection with any claim made against Indemnitee: 

(a) Excluded Acts. Any acts or omissions or transactions from which an officer or director may not be relieved of liability under
Delaware Law; 
 (b) Claims Initiated by Indemnitee. With respect to proceedings or claims initiated or brought
voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or any other statute or law, but such indemnification or advancement of expenses
may be provided by the Company in specific cases if the Board of Directors has approved the initiation or bringing of such suit; 

(c) Lack of Good Faith. For any expenses incurred by the Indemnitee with respect to any proceeding instituted by Indemnitee to
enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by the Indemnitee in such proceeding was not made in good faith or was frivolous; 

(d) Claims Under Section 16(b). For expenses and the payment of profits arising from the purchase and sale by Indemnitee of
securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute; 

(e) Insurance Payments. To the extent that payment is actually made to the Indemnitee under a valid, enforceable and collectible
insurance policy of the Company, and in the event the Company makes any indemnification payments to the Indemnitee and the Indemnitee is subsequently reimbursed from the proceeds of insurance, the Indemnitee will promptly refund such indemnification
payments to the Corporation to the extent of such insurance reimbursement; or 
 (f) Judicial Determination. In
connection with a judicial action by or in the right of the Company, in respect of any claim, issue or matter as to which the Indemnitee shall have been adjudged to be liable in the performance of his or her duty to the Company unless and only to
the extent that any court in which such action was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, the Indemnitee is fairly and reasonably entitled to indemnity
for such expenses as such court shall deem proper. 
 10. Security. To the extent requested by Indemnitee and approved by the
Board, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to
Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee. 

  
 -8- 

 11. Effectiveness of Agreement. To the extent that the indemnification permitted
under the terms of certain provisions of this Agreement exceeds the scope of the indemnification provided for under Delaware law, such provisions shall not be effective unless and until the Company’s Certificate of Incorporation authorizes such
additional rights of indemnification. In all other respects, the balance of this Agreement shall be effective as of the date set forth on the first page. 

12. Construction of Certain Phrases. 

(a) For purposes of this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents,
so that if Indemnitee is or was a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to
the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued. 

(b) For purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to
“fines” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent
of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants, or beneficiaries. 

13. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall constitute an original. 

14. Successors and Assigns. This Agreement shall be binding upon the Company and its successors and assigns, and shall inure to the
benefit of Indemnitee and Indemnitee’s estate, heirs, legal representatives and assigns. 
 15. Modification and Waiver. No
supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 
 16. Attorneys’ Fees. In
the event that any action is instituted by Indemnitee under this Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys’ fees, incurred by
Indemnitee with respect to such action, unless as a part of such action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action were not made in good

  
 -9- 

 
faith or were frivolous. In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this Agreement, Indemnitee shall
be entitled to be paid all court costs and expenses, including attorneys’ fees, incurred by Indemnitee in defense of such action (including with respect to Indemnitee’s counterclaims and cross-claims made in such action), unless as a part
of such action the court determines that each of Indemnitee’s material defenses to such action were made in bad faith or were frivolous. 

17. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed duly
given (i) if delivered by hand and receipted for by the party addressee, on the date of such receipt, or (ii) if mailed by domestic certified or registered mail, properly addressed with postage prepaid, on the third business day after the
date postmarked; otherwise a notice shall be deemed duly given when such notice shall be actually received by the addressee. Addresses for notice to either party are as shown on the signature page of this Agreement, or as subsequently modified by
written notice. 
 18. Choice of Law. This Agreement shall be governed by and its provisions construed in accordance with the laws of
the State of Delaware as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware. 

  
 -10- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written. 
  

					
	AGREED TO AND ACCEPTED	 		 	
			
	INDEMNITEE:	 		 	COMPANY:
			
	      
	 		 	      

	Address:	 		 	 By:
 Title:

Address:

			
	      

     

     
	 		 	 One Kendall Square, Suite B3301
 Cambridge, MA
02139
 Attn: Brian Pereira
 Fax:
(617) 498-1073

  
 [Signature Page to
Indemnification Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]